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ABSTRACT  
M. Kumi Smith: Treatment to Prevent HIV Transmission in Serodiscordant Couples in Henan, 
China 
(Under the direction of William C. Miller) 
 
 Suppressive antiretroviral therapy (ART) can prevent sexual HIV transmission by 
reducing viral concentration in the blood and genital tract of infected partners. Whether or not 
this effect can be achieved in the non-trial settings is a matter of debate. Aim 1 assessed the 
effect of ART on HIV transmission risk between partners in an open cohort of serodiscordant 
Chinese couples, past analyses of which have resulted in contradictory findings. Public health 
data collected for disease control purposes was used to analyze seven years of follow-up data for 
an open cohort of 4916 previously untreated HIV serodiscordant couples. Using marginal 
structural Cox proportional hazard models to weight for time varying confounding by treatment 
and censoring, we found that ART reduced the risk of HIV transmission by 55% (95% CI, 0.23-
0.88). However graphical plots of weighted survival curves and stratified analyses by time period 
indicated a lack of effect before 2009 (HR, 1.27, 95% CI, 0.39-4.11) followed by a much greater 
effect from 2009 onward (HR, 0.36, 95% CI, 0.19-0.68). This periodicity coincides with a phase 
of massive scale up and introduction of second line antiretrovirals in China’s free ART program, 
though the protective effect did not appear to vary by specific type of ART regimen. In Aim 2 
we used a data from the subset of the same couples who ever received ART in the course of 
follow-up (N=3939) to assess the impact of distance to the HIV care center and patient load per 
clinician on HIV transmission risk. Higher patient load (over 100 patients per clinician) was 
 iv 
 
significantly associated with higher risk of HIV transmission (HR=1.24, 95% CI, 1.27-4.03), 
particularly among those assigned to village HIV care centers (HR=2.26, 95% CI, 1.27-4.03). 
Adjusted Cox proportional hazards models found that living farther (>10 kilometers, km) from 
the clinic was associated with HIV transmission risk (HR=1.18, 95% CI, 0.44-3.1). We 
hypothesize that motivation for care seeking and minimum thresholds for distances willing to be 
traveled may differ by the tier of designated HIV care centers.  
 v 
 
ACKNOWLEDGEMENTS 
M. Kumi Smith was supported by the DHHS/NIH/NIAID (T32 AI 007001) from 2011 to 
2013, and by the Fulbright-Hays Doctoral Dissertation Research Abroad fellowship from 2014 
for the research and writing of this dissertation. She also received funding support from the UNC 
Carolina Asia Center Pre-Dissertation Asia Travel Award and the UNC Department of 
Epidemiology Nancy Dreyer Scholarship. She is grateful for these generous sources of support.  
Data used for this dissertation research came from records collected for routine disease 
control work by the Chinese Centers for Disease Control, made possible by the Chinese 
Government grant under the 12th Five-Year Plan (2012ZX10001-002).  
 vi 
 
TABLE OF CONTENTS 
LIST OF TABLES……………………………………………………………………………...viii 
LIST OF FIGURES ....................................................................................................................... ix 
LIST OF ABBREVIATIONS ......................................................................................................... x 
CHAPTER 1: Specific Aims ........................................................................................................ 11 
References ................................................................................................................................. 14 
CHAPTER 2: Background ............................................................................................................ 15 
Tables & Figures ....................................................................................................................... 31 
References ................................................................................................................................. 34 
CHAPTER 3: Research Design & Methods ................................................................................. 43 
Tables & Figures ....................................................................................................................... 56 
References ................................................................................................................................. 60 
CHAPTER 4: Aim 1 ..................................................................................................................... 61 
Tables & Figures ....................................................................................................................... 72 
CHAPTER 5: Aim 2 ..................................................................................................................... 80 
Tables and Figures .................................................................................................................... 92 
CHAPTER 6: Discussion ............................................................................................................ 101 
Tables & Figures ..................................................................................................................... 109 
 vii 
 
References ............................................................................................................................... 110 
APPENDIX 1. Neighbor Joining Tree........................................................................................ 112 
APPENDIX 2. Maximum likelihood tree ................................................................................... 114 
APPENDIX 3. Patient Interview Guide...................................................................................... 116 
APPENDIX 4. Provider Interview Guide ................................................................................... 120 
 viii 
 
LIST OF TABLES 
Table 2.1. Summary of ecological studies .................................................................................... 31 
Table 2.2. Studies of HIV serodiscordant couples ........................................................................ 32 
Table 3.1. Description of tiers of care in study prefecture............................................................ 56 
Table 4.1. Characteristics of the 4916 HIV serodiscordant couples included 
in the final analysis ........................................................................................................72 
Table 4.2. Incidence of HIV seroconversion in non-index partners by key 
covariates .......................................................................................................................73 
Table 4.3. Hazard ratios comparing ART exposed and unexposed 
serodiscordant couples ..................................................................................................74 
Table 5.1. Characteristics of  the healthcare system in study prefecture ...................................... 92 
Table 5.2. Characteristics of each tier of HIV care centers in the study prefecture ..................... 93 
Table 5.3. Characteristics of the 3939 HIV serodiscordant couples included in 
the final analysis ............................................................................................................94 
Table 5.4. Hazard ratios comparing HIV transmission risk in serodiscordant 
couples by distance to, and patient load of, HIV care center ........................................95 
Table 5.5. Mean time to HIV transmission among serodiscordant couples ................................. 96 
Table 6.1. Review of serodiscordant couple studies on treatment as prevention 
in China. ......................................................................................................................109 
 
 
 
 
 
 
 
 
 
 ix 
 
LIST OF FIGURES 
Figure 3.1: Map of study prefecture………………………….………………………………….55 
Figure 3.2: New User Design……………………………………………………………………56 
Figure 3.3: Theoretical causal graph demonstrating time-varying confounding………………..57 
Figure 4.1: Hazard ratios and 95% confidence intervals for effect of ART on 
       HIV transmission …………………..………………………………………………..72 
 
Figure 4.2: Weighted Kaplan Meir survival curves……………………………………………...74 
Figure 5.1: Distribution of HIV care centers and median distance by county in study 
prefecture……………………………………………………….………………...….96 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 x 
 
LIST OF ABBREVIATIONS 
 
AIDS  Acquired Immune Deficiency Syndrome 
CI  Confidence Interval 
HIV  Human Immunodeficiency Virus 
HR  Hazard Ratio 
IDU Injection Drug user 
MSM Marginal structural model 
STI Sexually Transmitted Infection 
 
 
 
 
 
 
 
 
 
 
 11 
 
CHAPTER 1: SPECIFIC AIMS 
 Antiretroviral therapy (ART) administered in clinical trial settings can effectively reduce 
heterosexual HIV transmission risk by suppressing the amount of virus in the blood and genital 
tract of the infected partner.
1
 Whether or not this effect can be achieved in the real world is a 
matter of debate. Critics argue that the requirements of durable and reliable viral suppression—
optimal drug regimens, routine lab monitoring, timely treatment of other infections, etc.— make 
this strategy unrealistic for immediate use in resource constrained settings.
2–4
 Supporters 
maintain that the preventive benefit of ART in the real world is already reflected in patterns of 
transmission at the population level
5
 and in the experiences of several cohorts of heterosexual 
couples where only one partner is HIV infected (known as “serodiscordant couples”).[Muessig, 
in press] Though most such studies confirm the promise of ART as a prevention tool, these 
reports of serodiscordant couples from China and Uganda found no statistically significant 
difference in transmission rates between treated and untreated couples followed from 2006 to 
2008, weakening the central tenet of the treatment as prevention strategy.
6
  Follow-up of the 
Chinese cohort has been ongoing, and an analysis of data from 2008 and 2011 found that ART 
was instead protective against transmission,
7
 raising further questions about the relationship 
between ART exposure and HIV transmission in non-trial settings.  
 Unlike most of the other studies reporting protective effects of ART, the Chinese patients 
were not managed under special conditions but were rather recipients of routine medical care. 
Decentralization of HIV treatment to community health centers has been crucial to China’s rapid 
roll out of its national free ART program,
8
 but may have bred inconsistencies in treatment 
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outcomes across local care settings. Receiving primary care at village level clinics (as opposed to 
at a town or county healthcare centers) was recently found to be predictive of virological failure 
in a random sample of rural HIV patients in China, as was exposure to ART regimens containing 
the antiviral agent didonosine.
9
 Additionally, members of the original Chinese couples cohort 
participating in recent qualitative interviews reported widely different experiences regarding 
availability and accessibility and quality of HIV care. A successful treatment as prevention 
program will require that ART delivered under real-world conditions like rural China provides 
adequate viral suppression for its use as a prevention tool. The Chinese leadership has already 
demonstrated initiative in using treatment to prevent HIV, underscoring the importance of 
understanding why ART failed to provide consistent protection against HIV transmission in this 
cohort. 
 We hypothesized that ART can reduce risk of HIV transmission, and that its efficacy may 
vary across key factors such as choice of antiviral agents or characteristics of the HIV care 
delivery model. To test this hypothesis, we investigated how these factors may have shaped the 
efficacy of ART on HIV transmission risk in the Chinese cohort by 1) refining our exposure 
variable to incorporate information on the specific agents and patterns of antiviral use and 2) 
developing new variables to measure characteristics of patients’ designated HIV care centers. By 
accounting for systems-level features and by using the entire observation period (2006-2012), 
this analysis provides a more comprehensive picture of ART efficacy on HIV prevention in rural 
China. Specifically we proposed to: 
Aim 1. Assess the efficacy of ART on HIV transmission in serodiscordant couples in 
Zhumadian between 2006 and 2012. We combined data from the initial (2006-2008)
6
 and 
subsequent phases (2008-2011)
7
 of follow-up of serodiscordant couples in the study prefecture. 
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to build a comprehensive database from which to estimate the effect of ART on HIV 
transmission over the entire observation period. We validated outcomes in the national 
epidemiology database and exposures in the national HIV treatment database.  
Aim 2. Determine the impact of a) distance to index partners’ designated HIV care 
center, and of b) the patient volume at each HIV care center,  on the preventive effect of 
ART on HIV transmission. We used geospatial methods to measure the travel distance between 
patients’ homes and their designated HIV care center, and assessed patient load per clinician to 
examine their impact on the protectiveness of ART against sexual HIV transmission. 
This dissertation improves upon the existing understanding of the efficacy of ART for 
HIV prevention outside of trial settings, and features of healthcare systems in resource 
constrained settings that may enhance or hinder the long term efficacy of this potential HIV 
prevention intervention. 
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CHAPTER 2: BACKGROUND 
Significance 
The concept of using ART to reduce infectiousness of HIV infected individuals is based 
on over two decades of clinical and epidemiological research.
1
 Early intuition about the 
importance of viral suppression to prevent HIV transmission
2
 and results of early randomized 
control trials (RCT) showing that ART could stop mother-to-child transmission
3
 provided a 
theoretical foundation for the use of ART for HIV prevention. Risk of sexual HIV transmission 
has been most closely linked with HIV RNA concentrations in the blood,
4–6
 which is a relatively 
reliable proxy for viral concentrations in the genital tract.
7,8
 ART for prevention of sexual HIV 
transmission hinges on the ability of antiretroviral agents to penetrate the male and female 
genital tracts
9,10
 and reduce viral shedding in these compartments. Treatment with ART can 
reduce (though not always eliminate
11
) HIV shedding in cervicovaginal secretions
12,13
 and 
semen,
14,15
 but factors such as co-occurring STIs,
16
 drug resistant viral variants in the genital 
tract,
17,18
 or choice of antiretroviral agent
19
 have all been associated with higher viral quantities 
in the genital tract of ART treated individuals.  
This body of research provides convincing evidence of the plausibility of using ART to 
control the amount of virus shed in the genital tract of treated individuals. Understanding the true 
implications of suppressive ART for prevention of sexual transmission, however, requires 
epidemiological data from the real world. To date the two major lines of investigation have 
involved analyses of HIV transmission in population level data (ecological studies, mathematical 
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modeling studies) and in HIV serodiscordant couples.  
 
Ecological studies 
 Analysis of changes in regional HIV epidemics in the presence of ART have been used to 
assess whether a treatment as prevention policy—generally described as frequent universal 
testing coupled with ART initiation immediately following diagnosis, and high degrees of viral 
suppressions for treated individuals
20—could be expected to slow population level HIV 
transmission. These studies take advantage of “natural experiments” found in settings like San 
Francisco or British Columbia (Table 1), where existing HIV control strategies have already 
achieved testing and treatment coverage rates to which future treatment as prevention strategies 
aspire. By examining the association between changes in ecological measures of population level 
infectiousness and HIV transmission in the community, these analyses can provide some 
understanding of the potential of a concerted treatment as prevention strategy.  
 Methodological limitations of these analyses, however, demand caution in interpretation of 
results.
21
 First, associations between ecological measures can detect relationships only at the 
group level and lack the person-level details necessary for testing etiological hypotheses.
22,23
 
Moreover statistical associations do not show causation, and observed trends could be due to 
factors other than population level suppression due to ART. Rising incidence in the very 
communities where a treatment as prevention strategy would be expected to be the most 
successful
24,25
 suggests that other forces could limit or reverse the preventive benefits of 
widespread testing and ART, including changes in sexual behavior in response to widely 
available ART,
26
 saturation of HIV in high-risk groups,
27
 in-migration of individuals from high 
prevalence regions,
20
 or the possibility that ART is less protective against transmission through 
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riskier modes like anal sex or needle sharing.
28–30
 Though some of these trends are widely 
acknowledged, only one of the reports described below formally controls for it in a regression 
model.
31
  Conversely, some of the studies attribute observed declines in HIV incidence, 
particularly among people who inject drugs, to widespread ART uptake, without 
acknowledgement of the role that other programs like safe injection sites or needle exchange 
may have played in the observed trends.
26
 Though any of these competing theories can provide 
plausible explanation for the lack of effect observed in some communities, the lack of data on 
these factors limits our ability to assess their impact on the associations of interest.  
 All but two of the above studies
25,32
 arrive at the same conclusion that increased population 
exposure to ART leads to lower HIV transmission. Although ecological studies can play an 
important role in the development of new HIV prevention strategies, they are methodologically 
limited to building justification of further formal scientific inquiry into population-level effects 
of the potential policies in question. They are therefore the first of many steps in the path from 
science to policy. 
 
Mathematical models 
 Mathematical models have been used to quantify and project dynamics of HIV epidemics 
in the presence of ART. In the absence of empirical data, mathematical modeling can be a 
powerful tool to inform public health decisions by calculating intervention impact, cost-
effectiveness, or resource allocation. However, these models are bounded by many assumptions.   
 We are aware of over 30 separate mathematical models that have been used to quantify and 
predict the population level impact of ART on HIV transmission, summarized in several 
extensive reviews on the topic.
33–36
 Although many modeling studies provide provocative 
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evidence that rapid ART scale-up could dramatically reduce
37–45—or even eliminate46—sexual 
HIV transmission, model plausibility can sometimes be a function of its ability to account for 
myriad contextual factors expected to affect program outcomes. More sophisticated models have 
accounted for factors such as changes in sexual behavior in response to treatment;
47–55
 sexual 
network patterns,
52,56
 sub-optimal ART efficacy from inadequate coverage, adherence, or 
efficacy;
57–59
 drug resistant HIV strains;
40,60
 differential infectiousness according to disease 
stage;
50,61,62
 and the limitations of suppressive ART provision in resource poor settings.
56,61,63
 
Predictably, the results of these models have been less optimistic.    
 Wide variation in model results can be attributed to the heterogeneity across model 
complexity as well as the diversity of the underlying assumptions fed into them. An informed 
tradeoff between simplicity and plausibility is central to effective application of their results; 
exceedingly complex models have limited generalizability and interpretability, but predictions 
generated by overly simplistic ones may be less informative. Harmonization across model choice 
and inputs is a central goal of modeling teams like the HIV Modeling Consortium at the Imperial 
College and South Africa Center for Epidemiological Modeling and Analysis, in order to build 
consensus on the fundamental elements of a successful treatment as prevention program.  
 
HIV Serodiscordant Couples Studies 
 HIV serodiscordant couple studies provide a critical window into the process of HIV 
transmission by allowing investigators to observe occurrence of viral transmission, beyond just 
the usual outcome of viral acquisition. They also provide the necessary person-level data to 
inform hypotheses on causal mechanisms driving HIV transmission. In cases where a subset of 
the initially infected or “index” partner is exposed to ART during follow-up, estimation of the 
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protective effect of ART on transmission is possible (Table 2).  
 However the complexity of this research design faces several barriers to valid estimation of 
true transmission risk. For one, investigators cannot exclude the possibility that infections 
observed in non-index partners are acquired outside the partnership, which past research has 
found to be the case in up to 30% of observed events.
64,65
  Sophisticated techniques of molecular 
virology to verify linkage between viral sequences of both partners can validate outcomes, but 
may be beyond the budget or technological capacity of many research teams. Second, cohorts 
may over-represent less vulnerable couples that are able to sustain discordancy far longer than 
those couples with “high and fast transmitters”66  that become concordant before having an 
opportunity to enroll in such studies. Oversampling of less infective index cases or less 
susceptible partners may lead to underestimation of transmission risk.
67
 Finally, results of these 
all of these studies are only generalizable to individuals in stable heterosexual relationships, 
though several large scale trials among male homosexual couples
68,69
 and injection drug users
70
 
are underway to close this information gap.  
 These concerns notwithstanding, evidence from these studies form compelling evidence that 
ART may prevent HIV transmission. First among them is the HPTN 052 trial whose findings 
that early ART reduces HIV transmission risk by 96% provides “gold standard” evidence of 
ART’s protective effect.10 Though its rigorous study design confers these results a high degree of 
validity, the trial environment make it difficult to assess translatability of these results to real 
world settings where few patients have the access to top-of-the-line antiretrovirals, intensive 
adherence counseling, or routine laboratory monitoring provided to HPTN 052 participants. Data 
from non-trial settings include results from retrospective
71–74
 and prospective
75–78
 studies that 
have followed a total of over 12,000 couples, in which all but two
79,80
 confirm the protective 
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effect of treatment against sexual transmission. Meta-findings of these studies are summarized in 
two recent reports.
67,81
  
 The results of the both studies which reported no protective effect of ART both arise from 
analyses of the experiences of serodiscordant couples in resource poor areas of Uganda
79
 and 
rural China.
80
 Debate on these findings have revolved around the utility of findings from rural 
settings that commonly lack routine viral load testing and where reliable ART delivery is limited 
by fundamental resource constraints.
82,83
 Though more details from the Ugandan cohort are 
forthcoming, ongoing follow-up of the Chinese couples cohort—hereafter the “Henan couples,” 
for the name of the study prefecture—have found that between 2008 and 2011, ART was instead 
highly protective against transmission,
84
 raising further questions about the relationship between 
ART and HIV transmission in non-trial settings. Closer examination of these seemingly 
conflicting results from the Zhumadian cohort is the subject of this dissertation. 
 
Treatment as Prevention in the Real World 
 The value of insight gained from analyzing the treatment experiences of the Henan couples 
depends to a certain extent on the vision of treatment as prevention programs to which one 
subscribes. The main appeal of using treatment to prevent HIV lays in its dual role as both a 
therapeutic agent and preventive tool. But our capacity to reap these benefits hinges on the 
assumption that existing ART programs can confer patients with sustained viral suppression 
necessary for reducing their infectiousness. Treatment programs in developing country settings 
such as rural China face various constraints that limit their ability to achieve such outcomes.
85,86
 
Sustained viral suppression is difficult for patients to achieve even in the best of circumstances, 
as it requires daily drug adherence and regular monitoring of viral levels in the blood. That rural 
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Chinese patients were less able to durably suppress their viral levels and prevent transmitting to 
their partners may be less surprising than useful for highlighting important gaps between clinical 
science and the real world. 
The Henan couples present a scientifically compelling opportunity to assess the efficacy 
of ART for prevention in such settings because of the lack of other HIV risks that might 
otherwise undermine outcome assessment. As a rural district in a socially conservative rural 
community, divorce or marital separation are uncommon, and multiple sexual partnerships are 
thought to be less common than in urban areas.
87
 Prevalence of other risk factors driving HIV 
infection in the non-index partner including injection drug use, male sex with other men, or sex 
with commercial sex workers are also low in Henan as compared to other regions in China.
88
 
Government crackdowns in the late 1990’s also eliminated the practice of unregulated blood 
collection common in the early 1990’s, which was responsible for much of the primary HIV 
infection in this population.
89
  
 Features of the Henan cohort also make their experiences highly relevant for future treatment 
as prevention strategies. Unlike the patients from most of the other serodiscordant couple studies 
who were treated under special conditions, these patients received care through a government-
administered program, and their HIV negative partners were routinely screened as part of local 
health department protocol. Such conditions are notably similar to those specified by treatment 
as prevention designs that call for universal annual HIV testing and immediate treatment of 
infected individuals.
46
 It is therefore imperative that we understand why treatment initially failed 
to prevent HIV transmission in this cohort. The Chinese leadership has already demonstrated 
great interest in this policy and have taken decisive steps towards national roll-out including a 
province-wide pilot project and four randomized control trials to assess the effect the preventive 
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effect expanded testing and treatment in sex workers, homosexual men, and heterosexual 
serodiscordant couples.
90,91
 Findings from the research proposed here can therefore play a timely 
and critical role in ensuring that China’s future treatment as prevention programs can effectively 
be carried out in the real world. 
 
Predictors of Virological Failure in Former Plasma Donors 
Despite its early denial about the HIV epidemic, since 2001 the Chinese government has 
taken decisive steps to address its HIV problem, most notably through the launch of a national 
free treatment program to subsidize ART for all eligible patients.
92
  The program is widely noted 
both for its scale – about 78.5% of the estimated population of eligible patients are currently on 
treatment
88
 – as well as its success – mortality rates among treated patients have fallen from 39.3 
to 14.2 deaths per 100 person years through 2009.
93
  
With expanded ART access, however, has also come an inevitable rise in population 
level rise of drug resistance. The rapid pace of program scale-up, and evolving guidelines that 
expanded the size of China’s treatment eligible population—the minimum threshold for initiation 
rose from 200 to 350 CD4 cells/µL in 2008
94—has meant that program coverage outpaced the 
program ability to deliver high quality service across the system. Care providers in resource poor 
rural areas also receive very little specialized training in AIDS care,
95
 and care seeking behavior 
is often hampered by fear of stigmatization from the community
96
 or even providers 
themselves.
97
 Laboratory resources are also few, in 2011 only 30% of treated HIV patients had 
received a viral load test in the last year.
93
 Suboptimal regimens and few resources for adherence 
counseling have contributed to rising prevalence of drug resistant strains in China—some 
estimates for which are as high as 54.67% after one year of ART
98—boding poorly for both 
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therapeutic outcomes and risk of transmission to sexual partners of these unsuppressed 
individuals. 
Heterogeneity in treatment outcomes across demographic, geographical, and HIV risk 
factor subgroups suggest that treatment environment plays an important role in suppressive ART. 
In terms of treatment response, former plasma donors fare better than most other HIV infected 
sub-populations, but their risk of virological failure is nevertheless high, and has been associated 
with factors including lack of adherence counseling
99
 tier of HIV are setting,
100
 and exposure to 
certain antiviral agents .
95
 
 
 Innovation  
A great deal of interest drives HIV research to close the gap between clinical science and 
effective HIV prevention in the real world. Several large scale community randomized trials for 
treatment as prevention are underway to provide foundations of evidence for implementation of 
treatment as prevention policy.
101
 Such studies are costly and slow moving, however, and in the 
meantime thoughtful use of observational data to examine ongoing effects in the community, 
may help close some key gaps in our understanding. Antiretrovirals and other HIV care services 
provided through China’s free program also provide a realistic representation of conditions in 
which many global populations without routine ART access may experience with program roll-
out. In these ways, experiences of these couples may not only inform prevention potential of 
ART for couples in other parts of China, but also for those in other developing countries.  
Innovations of the this study include the HIV serodiscordant couples study design, which 
provides a method to simultaneously assess risk factors for transmission and acquisition of HIV. 
Long follow-up (7 years) large sample size (about 5000 couples contacted annually), and 
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acceptable retention rates for such a low-cost study (over 78% over the entire observation period), 
all strengthen validity of estimates from this cohort. Rigorous surveillance of the epidemic by 
local health authorities has also generated a rich database of clinical outcomes in treated 
individuals as well as results from routine screenings of their uninfected partners. 
Primary methodological innovations of this study include measurement of ART as a 
time-varying variable and the use of marginal structural models to control for time varying 
confounding with the use of treatment and censoring weights. A secondary innovation is the use 
of existing geospatial data to calculate distances from patients’ homes to their primary HIV care 
centers as a proxy for healthcare access.  
Finally, this study also proposes an innovative and international partnership between HIV 
researchers in the US and China. The international collaboration between experts at the 
University of North Carolina Chapel Hill and the National Center for STD/AIDS in Beijing are 
conducted in the spirit of efforts by both sides to collaborate on large-scale research projects on 
health sciences, particularly in the field of HIV and STDs. 
 
Preliminary Studies  
Four past investigations of ART efficacy against HIV transmission have been conducted 
in this same study population, findings from which have all shaped this dissertation.  
 
Phylogenetic Linkage of HIV Transmission Events 
The first was a pilot study of phylogenetic linkage analysis of transmission events 
observed in the Henan couples. HIV RNA was extracted and amplified from stored blood plasma 
samples for 15 couples (or 30 individuals) who had experienced a transmission event between 
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2006 and 2008. Amplification of any target sequence (gag, pol, or env) had a success rate of 67%, 
but success of amplification for all three sequences was only 40.%. After aligning gag region 
sequences with reference sequences from the Chinese National AIDS Reference Laboratory, 
using Multiple alignment program for amino acid or nucleotide sequences software (MAFFT 6.0; 
http://mafft.cbrc.jp/alignment/software/), distances between sequences were calculated with 
Molecular Evolutionary Genetics Analysis (MEGA 5.05) using the Kimura 2-parameter model, 
and neighbor joining phylogenetic trees with bootstrap support were inferred using neighbor-
joining and consensus methods.  
Results of the neighbor joining and maximum likelihood phylogenetic trees (Appendix 1) 
were visually inspected for partners who were grouped together on a mono-phyletic branch with 
a high bootstrap value (>80). According to these criteria, four out of six (4/6) of the Henan 
couples were linked. Given the small sample size, the fact that we could only consider only a 
single gene (gag), and the lack of information about sample collection dates, meaningful 
interpretation of these results was not possible. Nor was a larger scale project using stored 
samples from Henan considered logistically feasible logistical challenges of phylogenetic 
analyses. Validation of the outcome for this dissertation was therefore limited to evidence from 
self-reported epidemiological data.   
 
The Henan Couples: Studies 1 and 2 
Two past analyses have analyzed the efficacy of ART on HIV transmission in the same 
population of HIV serodiscordant couples in Henan. The first analysis, “Study 1,” analyzed data 
from 2006 to 2008
80
 and the subsequent “Study 2” analyzed data from 2008 to 2011.84 Study 1 
used Cox survival analysis and found no discernable effect of ART on HIV transmission, for 
which the authors hypothesized that factors such as poor medication adherence, suboptimal 
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regimens, and exposure misclassification as possible explanations. Using the same methods, 
Study 2 found instead found that ART was highly protective against HIV transmissions in these 
same couples.  
Divergent results between the two studies may have ben due to differences in sample 
selection and methods of effect measure estimation. Regarding sample selection, Study 1 used 
only 35% of eligible couples who were available for analysis in 2008, possibly due to time 
constraints imposed by the one-time addition of 29 extra survey questions used to assess patient 
quality of life.  Study 2 only analyzed data from the 2007 onwards and largely relied on data 
collected after the establishment of the web-based reporting system in 2008.  It therefore 
theoretically reflects the experiences of the same couples as in Study 1; however, no formal 
linkage to records from Study 1 was made. 
Choice of statistical model and exposure assessment may have been inadequate for 
controlling several sources of bias. Traditional multivariate Cox models adjusted for CD4 and 
viral load which appropriately adjusts for confounding at baseline but which fails to address time 
varying confounding. In addition, ART exposure was measured as a time fixed “ever vs. never” 
exposure which may severely misclassify exposure status of couples who initiated ART later in 
the observation period.  
Methods used for this dissertation were chosen expressly chosen for the purpose of 
addressing these analytical shortcomings.  
 
Qualitative Sub-study on Facilitators and Barriers to HIV Care 
To better inform hypotheses about factors that might enhance or hinder the preventive 
effect of ART, we also conducted a qualitative sub-study consisting of in-depth interviews with 
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patients and providers from the study prefecture in Henan.. Interview guides were designed to 
identify facilitators and barriers to routine HIV care, which we theorized would affect treated 
index partners’ ability to sustain virological suppression and therefore reduce risk of HIV 
transmission his or her sexual partners. Interview guides were developed based on results of a 
literature review in English and Chinese on barriers to ART adherence in rural or developing 
country settings. Key informants including experts at the national and local level CDC, as well as 
experts on qualitative research methods in Chinese settings (Drs Yingying Huang, Gail 
Henderson, and Kathryn Muessig), provided input on these materials and guidance on study 
design, participant sampling schemes, and provided feedback on pilot interviews. Preliminary 
interview guides (Appendix 2) were pre-tested with two patient volunteers and one physician at 
the Zhumadian City infectious disease hospital. Participants provided verbal consent to have 
their interviews recorded, transcribed, and reviewed by study staff to assess interview quality and 
to inform future methods. Pilot interview content was reviewed and discussed by the study team 
to edit the interview guide for improved flow, culturally appropriate phrasing, and possible 
probing questions for key content areas. The content of pilot interviews was not directly included 
in the analysis.  
For the full study, HIV infected participants of the annual serodiscordant couple survey 
who had ever received ART were approached through primary HIV/AIDS care clinician 
(patients) by research staff to gauge interest in participating in in-depth, semi-structured 
interviews. Eligible provider participants, including physicians, nurses, pharmacists, and health 
officials or other staff who were involved in health care provision for HIV infected patients, were 
approached directly by study staff. Patient participants shared the same eligibility criteria as the 
overall parent study. Participants willing to provide informed consent took part in two-on-one 
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interviews in closed, unmarked clinic examination rooms, conducted in Mandarin Chinese and 
audio recorded unless otherwise specified (two participants declined audio recordings, for which 
notes were taken). Interviews for patients addressed participants’ experiences with routine care 
seeking for HIV related medical needs, barriers and facilitators to ART adherence, and attitudes 
and opinions about preventing HIV transmission to sexual partners.  Providers were asked about 
their own barriers or facilitators to helping their HIV patients sustain viral suppression, including 
their own attitudes towards HIV, personal experiences with stigma, and perceptions of 
institutional support for their work. In accordance with locally acceptable practices, participants 
were compensated with a 33ML bottle of cooking oil valued at about 70RMB (about 11USD) for 
their time and effort. Sampling was designed to maximize representativeness of patient and 
physician experiences from both high and low HIV prevalence settings. 15 patients and 4 
providers were interviews in two high prevalence counties, and 9 patients and 5 providers were 
selected from a low prevalence county. Transcribed and translated recordings of interviews as 
well as interview notes were reviewed to generate a set of general impressions and preliminary 
coding notes. These were summarized into two major themes, described below.  
The first theme was that of clinic resources available to HIV patients at their designated 
HIV care centers. This theme emerged through direct observation over the course of multiple site 
visits to HIV care centers across the study prefecture. Free ART and HIV care in rural areas of 
China is delivered through the existing three-tiered healthcare system made up of village clinics, 
township healthcare centers, and county hospitals. County-level health authorities described to us 
how they adapted this system to meet the needs of HIV patients by identifying subsets of 
healthcare sites to specialize in HIV care, a process in which sites are provided medical trainings 
for clinicians, in which clinic pharmacies are fitted for ART dispensation, and in which clinics 
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are provided electronic access to the national ART and HIV surveillance databases for direct data 
reporting. Antiretroviral drugs and HIV care is free to patients only at his or her designated HIV 
care center, with more severe cases referred up to higher tiers of care. Those who opt for HIV 
care outside of this referral chain must bear all medical costs themselves. According to county 
health officials, the decision of which specific healthcare clinics will specialize in HIV care is 
based on the geographic distribution of HIV patients in each county. Although all HIV care 
centers theoretically have the same basic capacity, we observed stark differences across tiers of 
care in terms of factors such as the overall level of medical training among clinic staff, and in-
house laboratory testing capacity. The availability of HIV related resources and services 
therefore varied widely depending on whether the designated HIV care center was a village, 
township, or county-tier healthcare centers.  
The second theme regarding travel distance to patients’ designated HIV care centers, 
emerged through the course of in-depth interviews. Patients living in the same village as their 
designated HIV care center described the convenience of being able to walk to collect their 
prescriptions or to receive treatment and care for acute events. By contrast, those living farther 
from their designated HIV care centers described longer travel distances as a hindrance for 
accessing routine and emergency care, particularly if arrangements such as child care or 
transportation had to be made. Patients who received HIV care locally also described their 
providers as members of their own social community, whereas those receiving care at higher tier 
centers described feeling more anonymous to their providers.  
Preliminary findings from these interviews suggest that the China’s community-based 
model of HIV care delivery has been critical to the success of its free treatment program, but 
may have also bred inconsistencies across different treatment environments. These findings 
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became an important link between findings of our primary analysis (Aim 1) and subsequent 
analyses (Aim 2).  
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Tables & Figures 
 
Table 2.1. Summary of ecological studies 
Author 
(year) 
Study 
Location 
Exposure: population level 
infectiousness 
Outcome: HIV transmission 
  Assessment Measure Assessment Measure 
Katz M et 
al. 
(2002)
25
 
San 
Francisco, 
USA 
Population in 
clinical care 
Annual prevalence of 
ART use in HIV 
infected 
bi/homosexual men 
identified in 
HIV/AIDS registry 
Convenience 
sample of 
bi/homosexu
al men 
Incidence estimated from 
1) HIV testing clinic and 
2) STI clinic, using 
incidence estimation 
algorithm 
Wood E 
et al. 
(2009)
31
 
Vancouver, 
Canada 
Convenience 
sample of 
injection drug 
users 
Biannual median 
community viral load 
Convenience 
sample of 
injection 
drug users 
Annual testing in a cohort 
of HIV negative injection 
drug users 
Castel AD 
et al. 
(2011)
32
 
Washington 
D.C., USA 
Population in 
clinical care 
Annual mean and total 
community viral load; 
portion with 
undetectable viral load 
Sentinel 
surveillance 
Annual numbers of newly 
diagnosed cases 
Das M et 
al. 
(2010)
102
 
San 
Francisco, 
USA 
Population in 
clinical care 
Annual mean and total 
community viral load 
Sentinel 
surveillance 
Annual numbers of newly 
reported HIV diagnoses; 
annual incidence from 
surveillance data using  
serological testing 
algorithm  
Fang C et 
al. 
(2004)
103
 
Taiwan 
(national) 
Time period Time period (pre- 
versus post-ART 
period) 
Sentinel 
surveillance 
Surveillance data used to 
calculate average annual 
HIV transmission rate 
(new /prevalent cases) 
Jin F et al. 
(2010)
104
 
Sydney, 
Australia 
No direct 
assessment 
Comparisons to 
previously reported 
portions of treated 
homosexual men in 
with undetectable VL 
Convenience 
sample of 
homosexual 
men 
Per-contact probability of 
transmission in 
bi/homosexual men 
Law M et 
al. 
(2011)
105
 
Australia 
(national) 
Population in 
clinical care 
Annual portion of 
treated patients with 
undetectable VL 
No direct 
assessment 
Reference to previous 
publication describing 
HIV incidence trends 
during same period 
Montaner 
J et al. 
(2010)
106
 
British 
Columbia, 
Canada 
Population in 
clinical care 
Annual numbers of 
HIV patients receiving 
HAART; annual mean 
community viral load 
Sentinel 
surveillance 
New HIV positive tests 
per 100 population 
Porco et 
al. 
(2004)
107
 
San 
Francisco, 
USA 
Probability 
sample of 
bi/homosexual 
men 
Predicted per-contact 
infectivity based 
during the pre- and 
post-ART period 
Probability 
sample of 
homosexual 
men 
Annual testing in a cohort 
of HIV negative 
bi/homosexual men 
Tanser F 
et al 
(2013)
108
 
KwaZulu-
Natal, S 
Africa 
Population 
based cohort 
Population level ART 
coverage rates 
Population 
based cohort 
Results of HIV-
uninfected repeat testers 
in surveillance system 
Caption: Table 2.1: A summary table of studies that assess the association between population 
level ART exposure and HIV transmission using at least one ecological measure. STI: sexually 
transmitted infection. VL: viral load. 
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Table 2.2. Studies of HIV serodiscordant couples 
Author 
(Year) 
No of 
couples 
Study design & 
population 
Trans-
mission in 
treated 
couples 
Trans-
mission in 
untreated 
couples 
Conclusions 
Birungi 
Jel al. 
(2012)
79
 
586 
Prospective cohort of 
clients of an AIDS 
support organization 
and their negative 
partners 
9/352 8/234 
ART was not associated with 
reduced risk of HIV transmission in 
serodiscordant couples in a rural 
program in Uganda without viral 
load testing. 
Castilla J 
et al. 
(2005)
71
 
393 
Retrospective study of 
HIV clinic patients and 
their seronegative 
partners 
2/80 27/313 
Combined ART according to 
current guidelines have a great 
potential for preventing HIV 
transmission to sexual partners. 
Cohen M 
et al, 
(2011)
10
 
1763 
Serodiscordant couples 
prospectively enrolled 
in randomized control 
trial to compare early vs 
delayed ART   
1/866 27/877
a
 
Early ART was associated with 
96% reduction in risk of HIV 
transmission as compared to regular 
ART. 
del 
Romero J 
et al. 
(2010)
75
 
625 
Prospective study of 
couples recruited 
through HIV+ patients 
at an HIV/STI clinic 
0/191
b
 5/341 
Heterosexual infectivity of HIV-1 I 
individuals taking effective 
antiretroviral treatment is low. 
Donnell 
et al. 
(2010)
109
 
3381 
Prospective study of 
HIV+ and HSV+ 
individuals and their 
HIV- partners from the 
Partners in Prevention 
HSV/HIV Transmission 
Study 
1/349
 c
 102/3032
c
 
Molecular virology to established 
linked transmissions. Provision of 
ART to HIV-1 infected patients 
could be an effective strategy to 
achieve population-level reductions 
in HIV-1 transmission. 
Jia Z et 
al. 
(2012)
72
 
38862 
Retrospective analysis 
of all HIV infected 
individuals identified in 
the national 
surveillance database 
who have negative 
partners 
0/112 5/227 
Transmission risk reduced 35% in 
the first year of treatment, an effect 
which becomes non-significant after 
the fourth year of treatment.  
Melo M 
et al. 
(2008)
76
 
93 
Prospective study of 
HIV clinic patients and 
their seronegative 
partners 
0/41 6/52 
Transmitters showed significantly 
higher median viral loads, 
suggesting that heterosexual 
transmission of HIV is more a 
function of viral load than gender of 
index case. ART use may play a 
role in the prevention of HIV-1 
heterosexual transmission.  
Mussico 
et al. 
(1994)
73
 
436 
Retrospective study of 
HIV+ clinic and HIV 
surveillance center 
clients and their 
seronegative partners 
6/64 6/52 
ART in HIV-1 infected men 
reduces, but does not eliminate, 
heterosexual transmission of 
infection. 
Reynolds 
et al. 
(2010)
74
 
250 
Retrospective study of 
serodiscordant couples 
offered free ART if 
eligible 
0/32 42/218 
HIV-1 transmission may be reduced 
among HIV-1 discordant couples 
after initiation of ART due to 
reductions in viral load and 
increased consistent condom use. 
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Sullivan 
et al. 
(2010)
77
 
2993 
Prospective cohort of 
serodiscordant couples 
initiated on ART if 
eligible 
4/808
 b
 264/2125
 
 
ART was associated with a 94% 
reduction in transmission; ART 
initiation is a critical component of 
a package of biomedical and 
behavioral prevention services.  
Wang et 
al. 
(2010)
80
 
1927 
Retrospective analysis 
of former plasma 
donors and their 
seronegative spouses 
18/540 66/1303 
Transition events occurred with 
equal frequency in couples 
regardless of whether  the partner 
was provided ART. 
Wang et 
al. 
(2013)
84
  
4499 
Prospective cohort of 
former plasma donors 
and their seronegative 
spouses 
77/3505 23/583 
Trends in declining HIV incidence 
over time was significantly 
associated with ART in the index 
partner. 
Watera et 
al. 
(2009)
78
 
138 
Prospective cohort of 
couples identified at 
HIV testing center 
0/45 3/93 
ART seems to be associated with a 
particularly low risk of HIV 
transmission.  
 
Caption: Table 2.2. 
a
 “Untreated” couples had standard of care ART; b Mono or dual therapy; c 
Genetically linked transmissions.  
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CHAPTER 3: RESEARCH DESIGN & METHODS 
 The study design, study populations, and outcome assessments for the first and 
second aim were identical, and so are only described briefly for the second aim. Separate 
exposures that were used for Aim 2 are described in that section. 
 
Study Setting and Population 
 Our study prefecture is located in the south of Henan, a rural province in the central plains 
region of China (Figure 3.1). The HIV epidemic in Henan Province is largely attributed to 
unsanitary blood/plasma selling practices prevalent in the mid-1990’s which resulted in the 
largest known cohort of individuals infected through commercial blood selling in the world.
1
 By 
the time government crackdowns effectively ended these practices in 2000, entire villages of 
former donors had been infected with HIV, with estimates of the total number of HIV infected in 
Henan in 2004 ranging from 50 to 170 thousand.
2,3
  Among all prefectures with reported HIV 
cases,  those living in our study prefecture made up 19,927 or 38.1% of all cases reported in the 
province at the time
2
 (Figure 3.1). 
 In 2006 officials at the disease control center (CDC) of the study prefecture initiated follow 
up of an open cohort of HIV serodiscordant couples living in the prefecture, with technical 
guidance from investigators at the National Center for AIDS/STD Control & Prevention. The 
cohort included couples meeting all of the following eligibility requirements: 1) registered 
residents of the study prefecture, 2) over 
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16 years of age, 3) in a stable marriage (no separation or divorce), 4) in a HIV serodiscordant 
couple at the time of enrollment and 5) willing to provide informed consent. HIV status of both 
partners was confirmed at enrollment through enzyme-linked immunosorbent assay (ELISA; 
Wantai, Beijing, China) conducted by county-level CDC’s, and positive test results are 
confirmed by Western Blot assay (Wantai, Bejing, China) carried out at the prefectural CDC 
laboratories.   
Couples took part in an annual survey questionnaire in which partners were interviewed 
separately in face-to-face interviews with trained county-level CDC staff in their native dialect. 
Participants provided information on demographic characteristics, behaviors including 
extramarital sex and condom use, medical histories including sexually transmitted infection (STI) 
diagnoses, and history of, or plans for migration to other cities or provinces. HIV infected index 
partners provide additional information on HIV/AIDS related medical history including dates of 
ART initiation, regimen changes, or termination. Routine patient follow-up dictated regular CD4 
testing for all HIV infected individuals, conducted at the county level CDC with guidance from 
the prefectural health authorities. According to national guidelines, viral load testing was only 
conducted for individuals after ART initiation, making this information unavailable for all 
unexposed person years. Non-index partners underwent HIV testing at each annual survey, and 
individuals who tested positive are referred to their county-level CDC for posttest counseling and 
screening for treatment eligibility. Beginning in 2008 a centralized web-based reporting system 
was established to facilitate data collection and to allow direct enrollment of newly identified 
serodiscordant couples.  
In the first year of the survey 3407 couples participated; by 2012 an additional 1878 
couples had been enrolled, for an overall retention rate of 78.8% over the entire survey period. 
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The average age of index partners in 2008 was 44.2 ± 7.69 years (range 30-69). 90.4% of them 
reported “farmer” as their occupation, and 83.6% reported sexual intercourse in the past 3 
months. 
 
HIV/AIDS Care Delivery in Henan 
 Henan was one of the earliest pilot sites for China’s national ART program, which began 
in 2002. Early pilot sites were strategically located in regions hardest hit by the blood selling 
epidemic, in order to channel lifesaving drugs directly to patients in this region who had been 
infected longer and were therefore in most advanced stages of disease. To facilitate rapid 
distribution of ART and other HIV care, policy makers used a decentralize model to deliver 
services to even remote rural areas through the existing three-tier healthcare system of village, 
township, and county level healthcare centers
4
 (Table 3.1). To accommodate the uneven 
geographic distribution of persons living with HIV, county level health officials designated 
specific facilities to specialize in HIV care and treatment based on the prevalence patterns of 
their county. Designated HIV care centers were fitted with additional capacity for dispensing 
ART and for filing electronic case reports and patient charts to the national health authorities. In 
addition clinical staff received training in HIV/AIDS care, sometimes through collaborations 
with international organizations. HIV patients were eligible for fully subsidized care at their 
designated HIV care center, with more severe cases referred up to higher tiers of care. HIV care 
(but not ART) sought outside of this vertical referral chain was possible if patients were willing 
to bear the entire cost themselves.  The tier of clinic to which patients of a given county were 
assigned depended on the officials’ reasoning of the most cost effective and convenient 
distribution of a combination of upper and lower tier clinics to provide care.  
 46 
 
 The diversity of AIDS delivery models is best captured through a description of its extremes. 
In the highest prevalence settings, a larger number of healthcare facilities are designated as AIDS 
care centers, and, as the most prevalent type of healthcare facility, village clinics can be expected 
to make up the majority of such facilities, and, higher-level AIDS facilities will almost 
exclusively handle only the most critical cases. By contrast in lower prevalence counties, fewer 
facilities are designated as AIDS care centers but will also more likely be to a higher-level 
facilities such as a town or county level center. Through this model optimizes healthcare access 
for the patient population at large, it also inevitably disadvantages a minority of patients 
unfortunate enough to live far from his or her designated HIV care center. 
 The conceptual model of healthcare access as a multifaceted interplay between client and 
system is complicated in China by the government’s policy approach of channeling resources 
down to localities through the top-down state system. Although Chinese HIV patients without 
the economic means to pay for their healthcare at better care centers of choice, as a group they 
still exercise demand and choice, creating for a unique dynamic between patient demand for 
quality care and system supply of the “five A’s--availability, accessibility, affordability, 
acceptability, and accommodation.
5
 A better characterization of this dynamic is one of the key 
goals of Aim 2.  
 
Drug Regimens of the Free ART Program 
 The earliest antiviral agents available to Chinese HIV/AIDS patients through the free ART 
program were generic forms of zidovudine, stavudine, didanosine, and nevirapine. Nearly 80% 
of early patients were given a treatment regimen consisting of zidovudine, didanosine, and 
nevirapine,, with the remainder on stavudine instead of zidovudine due to complications with the 
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former. As more antiviral agents came off patent domestically produced generic version of 
indinavir became available. In addition starting in 2005 the China Ministry of Health began to 
import branded versions of efavirenz and lamivudine.
6
 
 
Aim 1 Study Design and Methods 
Study Design  
Our first aim was to determine the efficacy of ART on HIV transmission in 
serodiscordant couples in Henan who participated in at least two annual study visits between 
2006 and 2012. We hypothesized that exposure to ART regimens by the index partner reduced 
the hazard of HIV seroconversion in the non-index partner as compared to couples whose index 
partners were exposed to ART.  
Bias from differences in underlying risk rates between new and prevalent users of drug 
have been identified as key sources of bias in past pharmacologic analyses.
7
 We found that ART 
users who had initiated ART before study enrollment had a slightly lower risk of HIV 
transmission (0.35 cases per 100 person years) than their counterparts who initiated therapy 
while under observation (0.47 cases per 100 person years). This difference can be attributed to 
lower adherence among new initiates of ART who may be more likely to experience adverse 
drug effects or prescription to suboptimal regimens. Inclusion of prevalent users in our study 
may therefore confer even greater protectiveness to ART exposure and exaggerate the estimates 
down and away from the null. Inclusion of these individuals would also mean forfeiting the 
ability to control for their baseline factors that are themselves affected by the treatment, such as 
CD4. Exclusion of the 369 prevalent users in our new user design reduced the number of couples 
by 7.1%. Due to low rates of treatment termination (1.2%), all new users of ART were assumed 
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to continue therapy until they were censored. 
 
Primary exposure  
The primary exposure was ART in the index partner, which was measured as a time 
varying variable in which changes in exposure status are reflected in the values in each time 
interval within which the exposure status remains constant.  Information on patient ART regimen 
was extracted from the annual serodiscordant couple survey, and validated against information 
from the national treatment base. In cases where information from the two sources conflicted, 
preference was given to the data from the national database. 
 
Primary Outcome 
The primary outcome for this analysis was HIV seroconversion in the initially uninfected 
partner among enrolled couples who participated in at least two annual study visits between 2006 
and 2012. Seroconversion was calculated as the midpoint between the date of the last HIV-
negative or indeterminate antibody test, and three months before the date of the first positive 
HIV antibody test, to provide an average window period for seroconversion. Couples 
experiencing the outcome were censored in the interval in which estimated seroconversion 
occurred; those who remained discordant throughout the study were censored on the date of their 
last HIV negative test date. The outcome was validated by means of a manual review of results 
and dates of all HIV-positive test results in the national HIV surveillance database to which local 
and regional disease control authorities must report all newly identified cases of HIV infection. 
In cases where results differed between the two databases, preference was given to the records in 
the national surveillance database.  
 49 
 
Statistical Analysis 
 A time-dependent marginal structural Cox proportional hazards model was used to 
estimate the causal effect of ART on HIV transmission in this cohort. Marginal structural models 
provide valid estimates of treatment effects from observational data when the effect of time 
varying exposures may be confounded by time-varying covariates that are simultaneously 
intermediate variables. The models are weighted with the inverse probability of each patient 
receiving treatment in order to eliminate associations between prior exposure and other risk 
factors for the outcome. By delinking the propensity for treatment initiation from the variables 
that predict both initiation and  risk of the outcome, these weights can address confounding by 
indication when exposures and risk factors are both time-varying. As a consequence, these 
variables are implicated in confounding whether they are included or excluded from the final 
models Figure 3.2 provides a hypothetical example of how time-varying exposures and 
covariates can result in conflicting model building criteria, showing how possible causal 
pathways from ART0 and ART1 to HIV transmission travel through unconfounded and 
confounded pathways through CD41, respectively. For these reasons, whether or not the final 
model includes CD41, the estimates generated by a standard Cox model of the effect in question 
in above will be biased.  
  To eliminate time-varying confounding by indication, the contribution of each subject i 
to the risk set calculation at each time interval was calculated using the following stabilized 
weight formula:  
    
∏          
 
     ̅     ̅    ) )
∏          
 
     ̅     ̅    )   ̅    ̅ )
 
where Ak represents time dependent treatment on day k, and Lk represents vector for all 
measured time dependent risk factors for the outcome, and overbars are used to represent 
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exposure ( ̅) or treatment history ( ̅). The stabilized weight itself therefore represents the degree 
to which the patient’s observed treatment is explained by their prognostic indicators. By 
weighting the final model with the inverse of these weights, we are able to deemphasize the role 
in the risk set of subjects whose prognostic indicators strongly agree with their actual treatment 
experience, and emphasizing the role of those whose treatment is relatively independent of the 
prognostic indications. The resulting weighted “ghost” population therefore looks far more 
uniform in terms of their propensity to receive the exposure, in that the association between the 
prognostic indicators at time t, L(t) no longer predict treatment at time t, and the causal 
association between treatment and the outcome are  the same as in the study population. 
 Pooled logistic regression models were then used to calculate the numerator and 
denominator of the subject specific weights separately:  
Numerator:                         ̅     ̅   )                  
Denominator:              (    | ̅     ̅     ̅    ̅)                      
                 )  
Covariates making up L included age, sex, occupation, time, and disease stage. Appropriate 
scaling of age was assessed by comparing likelihood ratio tests for rescaled, log transformed, 
polynomial, and splines versions. The predicted values estimates by these two models are used to 
calculated swi for each subject using the formula given on the previous page.  
The following time-dependent Cox proportional hazards model was then fit with the 
inverse standardized weights to provide a valid and unbiased estimate of the treatment effect on 
HIV transmission: 
        )     )        )       ) 
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where log[hi(t)] is the hazard of HIV transmission at time t, α(t) is the baseline hazard of HIV 
transmission, β1 is the unknown parameter representing the causal effect of ART on time to HIV 
transmission, and V are baseline covariates in the population. To accommodate subject-specific 
time-varying weights, the final model used pooled logistic regression models with time as a class 
variable to allow a separate intercept for each time, thus mimicking the baseline hazard in a Cox 
model.  
 
Stratified Analyses 
Measures of effect of ART on HIV transmission risk were estimated across the following 
subgroups: sex, age (≤45 vs >45), baseline CD4 cell count of index partners, type of regimen, 
and time period, with the inclusion of interaction terms.  
For assessment of effect across strata of drug regimen, we compared the different 
exposure categories of “no ART,” “ART without didanosine” and “ART with didanosine.” These 
were coded using disjoint indicators, using “no ART” as the referent category. 
 
Power and Sample Size 
 In order to test the hypothesis that ART treatment reduces the risk of sexual transmission, the 
following calculations describe the expected statistical power to detect a range of effects given 
our existing sample size. Based on the fewest number of couples to ever take part in the annual 
serodiscordant couple survey since 2006 we used a sample size of 3407, with an ART coverage 
rate consistent with that as reported in Study 2 of 85.7%. With a two-sided hypothesis with a 
Type I error rate of 0.05, and the rate of outcomes observed in the unexposed was 2.3 cases per 
100 person years. Follow up time was calculated at 7 years, from 2006 to 2012, we estimated 
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having about 70% power to detect the same effect measure as reported in Study 1 (Figure  
 
Aim 2 Study Design and Methods 
 The purpose of my second aim was to determine the impact of accessibility and quality of 
HIV-related care, measured in terms of 1) patient volume per clinician at the designated HIV 
care center, and 2) distance to one’s designed HIV care center and on the preventive effect of 
ART on HIV transmission. The effect from healthcare access to HIV transmission risk was 
assumed to be connected through the pathway of viral suppression of index partners due to 
adherent use to ART. This pathway was hypothesized to operate through the improved clinical 
response expected among ART patients who more routinely seek care from their primary HIV 
care provider, thus increasing the likelihood of early identification of virological failure either 
through clinical or laboratory screening, by increasing frequency of adherence messaging, or by 
necessary adjustments of less tolerable or suboptimal drug regimens. Behavioral drivers of 
transmission including frequency of sex and condom use were not assumed to vary by level of 
access to healthcare and so were not considered in the final model. To isolate estimation to 
effects traveling through this pathway we restricted analysis of Aim 2 to the subset of couples 
whose index partner had ever receive ART between 2006 and 2012. 
 
Primary exposures 
 Our second aim consisted of two separate exposures, patient load per clinician, and 
distance from treated index partner’s village of residence to his or her designated HIV care 
center.  To estimate patient load, clinic level characteristics of designated HIV care centers at 
which at least one patient from our study sample was assigned was collected in the form of a 
 53 
 
survey distributed to the county level health authorities, through which information on clinic tier 
(village, town, or county), numbers of medical staff, and numbers of treated and untreated HIV 
patients per clinic were obtained. Patient load was calculated as the total number of HIV patients 
(regardless of ART status) at each HIV care center, divided by the total number of doctors and 
nurses at that care center. Both patient load and distance to clinic reflect the state of these 
measures as of 2012. 
 Patients’ villages of residence were extracted from reported addresses in the most recent 
survey data in the serodiscordant couple database, or, if missing this information, from the 
national epidemiology or treatment databases. Addresses of designated HIV care centers were 
provided by county level health authorities who indicated the specific care center to which 
treated patients from villages in our sample were assigned. Chinese language addresses were 
uploaded into an online geomapping service to generate estimated latitudes and longitudes for 
each point, from which Euclidean distance in kilometers (km) was calculated using the 
GEODIST function in SAS 9.3 (SAS Institute, Cary, North Carolina, USA).  
  
Primary Outcome  
 The measurement and coding of the outcome variable of HIV seroconversion in the 
initially uninfected partner was the same as was used for our first aim.  
 
Statistical Analyses 
 Univariable Cox PH regression analyses were first used to determine the appropriate 
functional form of both exposures. Next, both variables were visually assessed by plotting these 
measures against risk of HIV transmission when measures were coded linearly, categorically, 
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and as a quadratic spline. The decision to bifurcate distance at ≤10km and >10km was further 
informed by informal observation of common modes of transportation in the study prefecture 
where access to electric bicycles, farm vehicles, and public buses were common.  A validation 
sub-step was conducted for 200 randomly sampled individuals in which the geomapping service 
generated results were compared with manual entry of start and stop points in Google Earth. 
 The two exposures were assessed independently to estimate the effect of these two 
measures of healthcare access on HIV transmission. Multivariable causal models were built with 
the guidance of directed acyclic graphs
8
 and informed by common adjustment practices 
identified in the literature.  
 For patient volume, causal models of its effect on HIV transmission took the following 
form of a Cox proportional hazards model:  
    )      
                  )      )   
 H0:    = 0; H0:    < 0. We hypothesize that receiving care at a village level facility will 
be associated with greater hazard of HIV transmission, controlling for distance and other factors 
believed the affect quality and HIV transmission at the same time.  
 The effect of distance on HIV transmission risk took the form of a standard Cox 
proportional hazards model as follows: 
    )      
            )      )   
 H0:    = 0; H0:    > 0. We hypothesized that 1) higher patient load at one’s designated 
HIV care center and 2) farther distance from a patient’s residence to his/her primary AIDS care 
facility would both be associated with elevated HIV transmission risk, controlling for quality of 
care and other potential confounders.  Regarding tiers of care, Based on the results of Ma et al, 
we expected that patients receiving care at village or township level clinics to experience less 
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ART efficacy than those receiving care at county hospitals based on a past study on virological 
failure in this population.
9
 On the other hand results from our qualitative study suggested that 
patients receiving care at county hospitals may be less satisfied and due to the less personal 
nature of the care they receive there.  
   
Stratification 
 Assumptions of multiplicatively of effects across sub-strata of tier of HIV care center 
were assessed using the following models: 
        )     )          )         )             )                  )   ) 
        )     )          )         )                 )              )   ) 
 H0:    = 0; H0:    ≠ 0 (for both models). We hypothesized that the coefficient of the 
interaction between type of facility and ART, and distance to facility and ART would be 
significant. An alpha value of 0.20 was used in recognition of limited power in detecting 
significance in more finely stratified data. Stratified estimates for the effect of 1) distance and 2) 
patient volume on HIV risk were then calculated for each tier of HIV care center (village versus 
town and county) by interacting this variable with the exposure of interest, in order to estimate 
subgroup-specific measures of effect.  
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Tables & Figures 
Table 3.1. Description of tiers of care in study prefecture 
  Advantages Disadvantages 
Upper tier level 
HIV care centers 
(county hospitals) 
 Best trained and specialized medical staff, 
most advanced medical equipment 
 HIV care and ART prescriptions provided 
at separate facilities (county hospitals vs. 
county CDC’s)  
 Widest availability of non-ART drug  Longer wait times, less individualized care, 
more bureaucratic red tape 
 Shortest turnaround on CD4/VL results  Care is only subsidized if patient is referred 
from lower tier HIV care centers 
 Widest availability of ART drug; 
regimens adjusted more easily 
 
Lower tier HIV 
care centers 
(township health 
centers, village 
clinics) 
 More individualized care, socialization w 
other patients 
 Most clinicians lack formal medical 
training and have no specializations, only 
basic medical equipment 
 Shorter wait times, less bureaucratic red 
tape 
 Low availability of non-ART drugs 
 All AIDS related care is subsidized  Longest turnaround time for CD4/VL 
results 
   Long process to change ART regimen 
Caption: Figure 3.1: Advantages and disadvantages of care accessed at each type of AIDs care 
facility in Zhumadian. 
 
 
 
 
 
 
 
 
 
 
 
 
 57 
 
Figure 3.1. Map of study prefecture    
                           
 
Caption: Figure 3.1: The relative location of Henan Province and the study prefecture outlined in 
black, within Henan province. Red dots show the geographic distribution of HIV cases among 
former plasma donors in the province. One red dot equals 20 infections (adapted from Dou et 
al
10
). 
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Figure 3.2. New User Design 
 
Caption: Figure 3.2. The new user design excludes prevalent users from analysis, among whom 
underlying risk may be systematically different than that of new users, given time varying risk 
patterns over the course of drug exposure.  
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Figure 3.3. Theoretical causal graph demonstrating time-varying confounding 
 
Caption: Figure 3.3: The graph illustrates the adjustment dilemma when a time-varying covariate 
is both a confounder and an intermediary of the exposure-outcome association. Adjustment of 
CD41 would block a direct pathway from ART0 to the outcome (blue line) while simultaneously 
unblocking an indirect pathway from ART1 to HIV transmission (red line). 
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CHAPTER 4: AIM 1 
Antiretroviral Therapy for Prevention of Sexual HIV Transmission in Serodiscordant Couples in 
Henan, China, 2006 to 2012 
 
Introduction  
  Antiretroviral treatment (ART) administered in clinical trial settings can nearly eliminate 
heterosexual HIV transmission risk by suppressing the amount of virus in the blood and genital 
tract of the infected partner.
1
 Whether this effect can be achieved outside of trial settings is a 
matter of debate.
2,3
 Critics argue that the requirements of durable and reliable viral suppression—
optimal drug regimens, routine lab monitoring, timely treatment for opportunistic infections and 
other concerns—make this strategy unrealistic in resource limited settings.4–6 Supporters claim 
that the potential benefit of ART is already reflected in the collective experiences of several 
cohorts of HIV serodiscordant couples where only one partner is infected.
7
  In two such studies 
from China
8
 and Uganda,
9
 however, HIV transmission persisted regardless of the infected 
partner’s ART use. Details of the Ugandan cohort are forthcoming, but a more recent analysis of 
the same Chinese couples from Henan Province—hereafter the “Henan cohort”—found that 
ART was since highly protective against transmission,
10
 raising further questions about the 
preventive potential of ART in non-trial settings
11
. Closer examination of these seemingly 
conflicting results of the Henan cohort is the subject of this report. 
 This cohort provides an important opportunity to examine the potential effect of ART on 
HIV as is likely to take place in the real world. The Chinese government provides free and 
universal ART to eligible patients through a decentralized system. Subsidized care and drugs 
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(mostly generic) are delivered to patients through the existing healthcare system, in many cases 
by nonphysician clinicians with minimal training.
12
 The program’s high coverage of the 
treatment eligible population
13
 makes it a remarkably realistic version of “treatment as 
prevention” strategies proposed for resource poor settings.14 Why fewer rural Chinese patients 
were able to sustain low enough viremia to afford their partners consistent protection may be less 
surprising than useful for highlighting important gaps between clinical science and the real world. 
This analysis uses existing data collected for public health purposes to investigate the 
efficacy of ART in preventing HIV transmission in serodiscordant couples in Henan using all 
years of available data (2006-2012).  
 
Methods 
Study Setting and Data Sources 
The Henan cohort is an artifact of a regional HIV epidemic largely attributed to 
unsanitary blood and plasma selling practices prevalent in the mid-1990’s.15 Government 
crackdowns ended these practices by 2000 by which time an estimated 50 to 170 thousand 
persons in the province were estimated to be living with HIV.
16,17
 38% of the HIV population of 
Henan live in the prefecture where this study is set.
8
 
As part of the government’s emergency response to the Henan HIV epidemic, in 2006 the 
prefectural disease control center began enrollment of an open cohort of HIV serodiscordant 
couples to track HIV transmission in married couples. According to local guidelines, eligible 
couples were 1) registered residents of the study prefecture, 2) over 16 years of age (the age of 
legal consent in China), 3) in a stable marriage (no separation nor divorce), 4) in a HIV 
serodiscordant couple at the time of enrollment and 5) willing to provide informed consent. HIV 
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status of both partners was confirmed at enrollment through enzyme-linked immunosorbent 
assay (ELISA; Lizhu, Zhuhai, Guangdong Province; Xinzhuang, Xiamen, Fujian Province) and 
positive test results were confirmed by Western Blot (WB) assay (Ou’ya, Hangzhou, Zhejiang 
Province), both of which were carried out carried out at the county or prefectural level disease 
control center laboratories.   
Eligible couples participated in annual surveys consisting of private and separate face-to-
face interviews for each partner in their native dialect with trained county-level disease control 
staff. Participants provided information on demographics and behaviors over the previous year 
including sexual contact within and without the primary partnership, diagnosis of STIs, drug use, 
and activities related to blood exchange (including injection drug use, blood selling, blood 
transfusions, use of blood products, or invasive medical procedures), and migration for work 
(seasonal migration for labor is common in this population). The initially HIV infected (or 
“index”) partners provided additional medical history including ART use and initially uninfected 
(or “non-index”) partners were screening for antibodies to HIV, with those testing positive 
referred to their local county disease control center for confirmatory testing  and treatment 
eligibility screening.  
 
Exposure, Outcome, and other Covariates 
The primary outcome for this analysis was time to HIV seroconversion in the initially 
uninfected partner of couples participating in at least two annual study visits between 2006 and 
2012. Seroconversion was calculated as the midpoint between the date of the last HIV-negative 
or indeterminate test, and three months before the date of the first positive-HIV test to provide an 
average window period for seroconversion. Couples experiencing the outcome were censored in 
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the interval in which estimated seroconversion occurred; those who remained discordant 
throughout the study were censored on the date of their last HIV negative test date. 
Seroconversion events were manually validated by comparing test results and dates in the 
national HIV surveillance database, a centralized web-based system
18
 to which local disease 
control authorities report all newly identified HIV cases. If results differed between the two sets 
of records, information from the national surveillance database was used. 
The primary exposure was time-varying ART use by the index partner. As with the 
outcome, we validated treatment status by comparing our records against those of the national 
ART database, and priority was given to national ART database information in the event of 
discrepancies. Additional index partner covariates including disease stage, AIDS related signs 
and symptoms, and laboratory indicators such as CD4 cell count and viral load were linked from 
the national epidemiology and treatment databases using a unique identifier.  
 
Statistical Analyses 
To minimize potential bias introduced by differential risk experienced across couples 
whose index partners initiate ART at different times, we restricted analysis to those who 
unexposed to ART at baseline. By excluding prevalent users, this “new user design19” eliminates 
the bias induced by 1) under-ascertainment of events likely to occur early in the course of 
therapy and 2) by our inability to control for baseline factors that are themselves affected by the 
treatment (e.g. CD4 cell count). Exclusion of the 369 “prevalent user” couples reduced the 
sample size by 7.1%. Due to low rates of treatment termination (1.2%), all new users of ART 
were assumed to continue therapy until they were censored. Variables for which information was 
missing for more than 20% of the sample were multiply imputed using Markov Chain Monte 
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Carlo simulation, and the resulting model estimates were combined using Rubin’s formula.20  
We used Cox proportional hazard models to estimate the association between index 
partner ART use and time to HIV seroconversion in non-index partners. To mitigate bias from 
time varying confounding variables that are also affected by prior treatment, we weighted our 
estimation of a marginal structural model (MSM) with the inverse probability of treatment and 
censoring to balance treatment groups at each time point.
21
 Stabilization with baseline indicators 
yielded an appropriate weight distribution (mean, 1.04; standard deviation; 0.24; range, 0.27-
13.02). The final model was estimated using pooled logistic regression using time as a class 
variable to allow a separate intercept for each time and for subject specific weight to vary by 
visit. 
Hazard ratios from the MSM were compared with those of ) unweighted models, both 
crude and adjusted; b) weighted models that adjusted for residual confounding by baseline 
variables identified by directed acyclic graphs;
22
 c) a model weighted only for the inverse 
probability of treatment but not censoring, and d) a complete case analysis restricted to couples 
with complete data.  
Additional analyses stratified estimates using interacting terms for index partner 
characteristics including sex, baseline CD4 cell count, ART regimen, and time period (2006-
2008 versus 2009 onwards, to reflect periods before and after availability of second line ART).  
The assumption of proportional hazards was relaxed after inspection of the log-log survival 
curve by interacting our time and exposure variables.  
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Ethical Approval 
All data used for this analysis were collected as part of prefectural disease control efforts. 
Ethical approval for the analysis of this data for research purposes was provided by the 
Institutional Review Board of the National Center for AIDS/STD Control and Prevention 
(NCAIDS) at the Chinese Center for Disease Control and Prevention.  
 
Results 
The final analysis included 4916 couples with a mean follow-up of 5.4 years (Table 4.1). 
The median age of index partners was 44 years (interquartile range: 40-49) and 52.3% were 
female. Half of index patients (46.8%) were initially infected through blood or plasma donation, 
and over 90% of them reported “farmer” as his or her primary occupation. Occupation and 
schooling were largely similar across partners, most (68.9%) of whom had six or fewer years of 
education. Of the 94.8% (N=4662) couples who reported any sex at most recent follow-up, 63.3% 
of them (N=3115) reported “always” using condoms. On their first study visits, only 8.4% of 
index partners had initiated ART, but by 2012, most (82.8%) were receiving therapy.  
Few uninfected partners reported any behaviors that might increase subsequent HIV 
acquisition from outside the partnership. Thirty two (0.65%) reported any episode of extramarital 
sex in, and in all but once case perfect condom use was indicated in these relationships. 
Information on past diagnoses of STIs became available in the final year of the study (2012), 
which showed that 13 uninfected partners (0.4%) received such a diagnosis in the previous year. 
In 26,389 total years of follow-up we observed 157 seroconversions (overall incidence, 
0.59 cases per 100 person years; 95% confidence intervals (CI), 0.51-0.70). Of these 
seroconversions, 84 occurred when the index partner had already initiated ART (incidence 0.43 
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per 100 person years, 95% CI.0.35-0.53) and 73 when not on therapy (incidence 5.87 per 100 
person years, 95% CI, 4.65-7.42; Table 4.2).  Couples who seroconverted were more likely to be 
farmers, have had more reported sex over the past year, lower reported condom use, have an 
index partner whose baseline CD4 cell count below 250, have an index partner who was 
diagnosed more than five years ago, and who seroconverted in the earlier phase of follow-up 
(before 2009).  
In earlier years of the study, generic drugs—some with known side effects such as 
didanosine—were used. However, didanosine exposure did not appear to elevate transmission 
risk (incidence 3.15, 95% CI, 2.29-4.32 versus 5.36, 95% CI, 3.90-7.35 among non-didanosine 
exposed person years). Viral load is only collected after HIV patients initiate ART; but using this 
information we assessed that 29.9% of index partners of seroconverting couples were virally 
suppressed at the time, versus 56.0% of those whose did not transmit to partners, measured at 
their most recent visit. 
In crude analysis, ART reduced the risk of HIV in treated couples by 29% (HR=0.71, 
95%CI: 0.34-1.45). Weighting couples by their inverse probability of treatment and censoring 
resulted in comparable estimates (HR=0.68; 95% CI, 0.34-1.39).  Adjustment for residual 
confounding by baseline indicators of treatment and censoring (disease stage, sex, age, 
occupation) lowered estimates for the weighted and unweighted models to 0.45 (95% CI: 23-
0.88) and 0.43 (95% CI: 0.22-0.84), respectively. In sensitivity analyses, weighting for treatment 
but not for censoring had little effect (HR=0.44, 95% CI: 0.22-0.86); as with restricting analysis 
to cases with complete information (HR=0.44, 95% CI: 0.28-0.69). Stratification by sex, index 
partner baseline CD4 cell count, ART regimen type, and time period showed that ART may be 
only slightly more protective for male rather than female index partners (HR=0.31, 95% CI, 
 68 
 
0.14-0.76 versus HR=0.39, 95% CI, 0.16, 0.94) and for index partners initiating ART at CD4 cell 
count above 250. We did not observe a noticeable difference of ART efficacy based on if index 
partners were exposed to didanosine (HR=0.31, 95% CI, 0.13-0.71) or not (HR=0.49, 95% CI, 
0.24-1.02).  
In comparing transmission risk over time (Figure 4.2) we observed a substantial 
difference in the effect of ART between the early phase of follow-up (2006-2008) and more 
recent years (from 2009 onwards).Specifically, we observed no effect of ART in the early period 
(HR=1.27; 95% CI: 0.39-4.11) whereas ART was effective in the later period (HR=0.36, 95% CI: 
0.19-0.68).  
 
Discussion 
Our report found that ART can reduce HIV transmission risk in serodiscordant couples in 
rural China. However the protective effect was neither perfect nor detectable in the early years of 
the government provided free ART program. The change in ART efficacy over time did not 
appear to be related to the drug regimen employed, even though in the early years drugs with 
more side effects were used. We speculate that the improved ART efficacy over time may be at 
least partially attributable to systems level factors over time, such as improvements in ART 
delivery systems
23
 or increased medication adherence support.
24
 
Our report expands on two previous analyses of the same population, the first of which 
reported no protective effect between 2006 and 2008;
8
 and the second which reported that ART 
nearly eliminated transmission risk from 2007 to 2011.
10
 To address possible sources of bias 
driving these results, our analysis used all available years of data (2006-2012) and validated 
exposure and outcome data against national disease control records. Our inclusion of more 
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eligible couples (3182 or 65% additional eligible couples in the same years of follow-up) 
mitigated potential selection bias and measurement of ART as a time varying exposure (versus 
status at last visit) captured shifting exposure distribution over time and minimized 
misclassification bias. Finally, by restricting analysis to couples already exposed to ART prior to 
enrollment in our new user design, we established clear temporality between baseline 
confounding variables, ART use, and transmission. These methodological strengths, together 
with weighting of models with visit-specific inverse probabilities of treatment and censoring to 
address time-varying confounding, allowed our estimates to more closely mimic those of a 
randomized trial.  
Whether ART reduces HIV transmission risk in stable Chinese couples—which it does—
may be secondary to the question of the magnitude and durability of this effect. We found that 
the hazard ratio of ART efficacy changed dramatically over time (Figure 4.2). Since hazard 
ratios average potentially time-varying period-specific hazard raios,
25
 its magnitude can vary 
depending on the duration of follow-up, which is a likely explanation for the seemingly 
conflicting conclusions of the earlier
8
 and later
10
 observation periods of the Henan cohort. 
Moreover, dominant modes of HIV infection in China have shifted from blood and plasma 
selling to riskier sex,
26
 resulting in notable changes in baseline characteristics of new ART 
patients over time.
23
 For this reason the 26% relative reduction of HIV transmission risk from 
ART use reported by authors who analyzed a nationally representative sample of over Chinese 
38,000 couples over eight years
27
 may in fact averaging over a series of highly diverse effects 
over time and across patient populations. Stratified analyses provided by these authors hint at the 
disparity of effects embedded in their large sample; for example, the relative risk reduction from 
ART use was far greater for couples whose index partner was infected through heterosexual 
 70 
 
contact (50%) rather than blood or plasma selling (33%); or for couples followed for shorter 
periods of time. A smaller study of about 1000 couples in Yunnan Province reported a strong 
protective effect in virologically linked transmissions from 2009 to 2011,
28
 though higher overall 
transmission rates in couples in Yunnan relative to Henan (1.5 versus 0.5 cases per 100 person 
years) indicate the need for strategies capable of adapting to local habits and treatment barriers. 
China’s scale-up of free ART and HIV care to over 100,000 patients by the end of 2011 
is nothing short of remarkable, and vastly improved survival rates even among the earliest 
beneficiaries in rural Henan.
29
  Decentralization of ART delivery to rural community health 
centers and task shifting of primary HIV care responsibilities to nonphysician doctors was key to 
rapid program rollout, but more resource intensive services such as routine laboratory monitoring 
or adherence counseling programs have developed more slowly over time. The type of healthcare 
facility where patients receive care and travel time to clinics have been cross-sectionally 
associated with outcomes such as poorer adherence
24
, virological failure
30
, and drug resistance.
31
 
The interdependence of systems-level factors and the suppressive ability of ART to protect 
sexual partners of treated patients is the subject of an ongoing analysis. Scale up of ART in areas 
of low coverage may therefore do well to bear in mind the differential time scales on which 
direct services (drugs) and ancillary services (adherence counseling, viral load testing) develop, 
especially when program implementers are forced to prioritize services due to resource 
constraints.   
The Henan couples make up a unique cohort particularly well suited for assessing effects 
of ART on HIV prevention. The relatively long observation period captures the effects of ART 
over a historically significant period of treatment scale-up in China. Many resource poor areas 
where treatment as prevention is expected to have the greatest impact have yet to achieve 
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Chinese ART coverage levels, and successful programs will need full grasp of potential trade-
offs in preventive efficacy during early stages of implementation. Moreover the HIV population 
of Henan is largely made up of older individuals with low reported rates of drug use or sexual 
promiscuity
23
 (corroborated by low rates of syphilis or reported STI-like symptoms in our 
cohort); as such, the seroconversions we observed are likely true representations of HIV 
transmission between primary partners, a hypothesis that could ideally be confirmed through 
phylogenetic linkage analysis had useable samples of stored plasma been unavailable. In addition 
results from this cohort are generalizable to the 13% or 56,000 persons diagnosed with HIV in 
China every year who report a stable relationship with uninfected partners.
27
  
Virtually all current normative guidelines call for immediate treatment of the infected 
case in a stable discordant couple as soon as possible after diagnosis to prevent a transmission 
event.
32,33
  The preventive role of suppressive ART makes it an appealing solution to the dual 
problem of equitable drug access and effective HIV prevention. On the basis of our observations, 
ART is an effective method for reducing HIV transmission risk in stable couples in China.  
China’s proposed strategy to strengthen universal and immediate ART for the prevention of 
HIV,
34
 may benefit from monitoring system to identify in real time groups at higher risk of 
treatment failure.  
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Tables & Figures 
Table 4.1. Characteristics of the 4916 HIV serodiscordant couples included in the final 
analysis 
    Seroconversion   No seroconversion   Total 
    N=157   N = 4759   N = 4916 (%) 
Sex of index partner 
     
 
Male 69 
 
2177 
 
2246 (45.7%) 
 
Female 86 
 
2487 
 
2573 (52.3%) 
 
Missing 2 
 
95 
 
97 (2.0%) 
Age of index partner 
     
 
<45 73 
 
2504 
 
2577 (52.4%) 
 
≥45 84 
 
2255 
 
2339 (47.6%) 
Index partner HIV transmission route 
     
 
Blood/plasma donation 101 
 
2301 
 
2302 (46.8%) 
 
Blood transfusion 10 
 
705 
 
715 (14.5%) 
 
Injection drug use 4 
 
122 
 
126 (2.6%) 
 
Hetero or homosexual sex 18 
 
1270 
 
1288 (26.2%) 
 
Missing 24 
 
461 
 
485 (9.9%) 
Index partner occupation 
     
 
Farmer 153 
 
4307 
 
4460 (90.7%) 
 
Non-farmer 2 
 
352 
 
354 (7.2%) 
 
Missing 2 
 
100 
 
102 (2.1%) 
Index partner education level 
     
 
Primary or less 86 
 
3299 
 
3385 (68.9%) 
 
More than primary  58 
 
948 
 
1006 (20.5%) 
 
Missing 13 
 
512 
 
525 (10.7%) 
Monthly average frequency of sex 
     
 
0-2 11 
 
1429 
 
1440 (29.3%) 
 
3 or more 140 
 
3209 
 
2249 (45.7%) 
 
Missing 6 
 
272 
 
278 (5.7%) 
Condom use 
  
   
 
Always 36 
 
2871 
 
2907 (59.1%) 
 
Sometimes 11 
 
156 
 
167 (3.5%) 
 
Never 7 
 
23 
 
30 (0.6%) 
 
Missing 103 
 
1709 
 
1812 (36.9%) 
Index partner baseline CD4 
     
 
<250 66 
 
1520 
 
1586 (32.3%) 
 
≥250 66 
 
2735 
 
2801 (57.0%) 
 
Missing 25 
 
504 
 
529 (10.8%) 
Time since index HIV diagnosis 
     
 
<5 years 5 
 
496 
 
501 (10.2%) 
 
≥5 years 133 
 
4158 
 
4291 (87.3%) 
 
Missing 19 
 
105 
 
124 (2.5%) 
Index ART use (ever) 
     
 
Yes 101 
 
3851 
 
3952 (80.4%) 
 No 56   908   964 (19.6%) 
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Table 4.2. Incidence of HIV seroconversion in non-index partners by key covariates 
    Events Person Years Cases/1000PY (95% CI) 
Sex of index partner 
    
 
Male 69 12045 0.57 (0.45-0.72) 
 
Female 86 13915 0.62 (0.50-0.76) 
 
Missing 2 429 0.47 (0.12-1.86) 
Age of index partner 
    
 
<45 73 14072 0.52 (0.41-0.65) 
 
≥45 84 12317 0.68 (0.55-0.84) 
Index partner HIV transmission route 
    
 
Blood/plasma donation 101 12115 0.83 (0.69-1.01) 
 
Blood transfusion 10 4084 0.24 (0.13-0.45) 
 
Injection drug use 4 710 0.56 (0.21-1.50) 
 
Hetero or homosexual sex 18 7294 0.25 (0.16-0.39) 
 
Missing 24 2186 1.10 (0.73-1.63) 
Index partner occupation 
    
 
Farmer 153 24015 0.64 (0.54-0.75) 
 
Non-farmer 2 1923 0.10 (0.02-0.42) 
 
Missing 2 451 0.44 (0.11-1.77) 
Index partner education level 
    
 
Primary or less 73 18454 0.40 (0.31-0.50) 
 
More than primary  13 2699 0.48 (0.28-0.83) 
 
Missing 71 5236 1.36 (1.08-1.71) 
Average monthly frequency of sex in the past year 
    
 
0-2 124 15456 0.80 (0.67-0.96) 
 
3 or more 29 9370 0.31 (0.22-0.45) 
 
Missing 4 1563 0.26 (0.10-0.68) 
Condom use 
  
  
 
Always 54 15981 0.34 (0.26-0.44) 
 
Sometimes 16 736 2.17 (1.34-3.53) 
 
Never 9 104 8.65 (4.63-16.16) 
 
Missing 78 9568 8.15 (0.65-1.02) 
Index partner baseline CD4 
    
 
<250 66 8651 0.76 (0.60-0.97) 
 
≥250 66 15747 0.42 (0.33-0.53) 
 
Missing 25 1991 1.26 (0.85-1.85) 
Estimated time of index HIV diagnosis 
    
 
<5 years 5 1923 0.26 (0.10-0.62) 
 
≥5 years 133 22978 0.58 (0.49-0.69) 
 
Missing 19 488 3.89 (2.51-6.05) 
Index ART user (ever) 
    
 
Yes 90 20769 0.43 0.35-0.53) 
 
No 66 1124 5.87 (4.65-7.42) 
ART status 
    
 
Regimen contains didanosine 5 1589 0.31 (0.13-0.75) 
 
Regimen does not contain didanosine 79 14749 0.54 (0.43-0.67) 
 
Not treated (naïve or terminated) 73 10051 0.73 (0.58-0.91) 
Time period 
    
 
2008 and earlier 86 10160 0.85 (0.69-1.04) 
 After 2008 71 16229 0.44 (0.35-0.55) 
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Table 4.3. Hazard ratios comparing HIV transmission risk in ART exposed and unexposed 
serodiscordant couples  
    HR 95% CI 
Main analysis (crude) 
   
 
Weighted 0.68 0.34 1.39 
 
Unweighted 0.71 0.34 1.45 
     Sensitivity Analyses (adjusted) 
   
 
IPTW only 0.44 0.22 0.86 
 
Complete case 0.44 0.28 0.69 
 
Weighted 0.45 0.23 0.88 
 
Unweighted 0.43 0.22 0.84 
     Stratified Analyses (weighted and imputed) 
   Sex of index partner 
   
 
Male 0.31 0.13 0.76 
 
Female 0.39 0.16 0.94 
Index baseline CD4 cell count (weighted w/ CD4) 
   
 
<250 0.89 0.31 2.57 
 
≥250 0.38 0.19 0.78 
ART regimen 
   
 
ART with didanosine vs no ART 0.31 0.13 0.71 
 
ART without didanosine vs no ART 0.49 0.24 1.02 
Time period 
   
 
2008 and earlier 1.27 0.39 4.11 
  2009 onwards 0.36 0.19 0.68 
 
Caption: Table 4.3: Adjusted models included variables for occupation, index partner age, index 
partner disease stage, index partner sex, and time period. IPTW, inverse probability of treatment 
weighting. IPCW: inverse probability of censorship weighting. MI: multiple imputation. 
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Figure 4.1. Hazard ratios and 95% confidence intervals for effect of ART on HIV 
transmission 
 
 
Caption: Figure 4.1: *Adjusted for baseline prognostic indicators, including baseline disease 
stage, occupation, age, and sex. 
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6
 
Figure 4.2. Weighted Kaplan Meir survival curves 
 
Caption: Figure 4.2: Inverse probability of treatment and censoring weighted Kaplan Meir survival curves comparing treated and 
untreated experiences of couples. The same curves are shown on two different scales (0 to 1 on the left and 0.9 to 1.0 on the right) 
to better illustrate the divergence. 
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CHAPTER 5: AIM 2 
Efficacy of Antiretroviral Therapy for Sustained Viral Suppression in Henan, China: 
Implications for Healthcare Delivery Systems 
 
Introduction 
Universal antiretroviral therapy (ART) coverage has become a central pillar of the global 
HIV agenda,
1–3
  propelled by the twin goals of equitable drug access for individuals and disease 
eradication through transmission prevention.
4
 Clinical challenges of helping patients sustain low 
enough viral levels to protect their sexual partners are considerable, particularly in developing 
settings constrained by limited laboratory resources, frequent interruptions to the drug supply, 
and inadequate adherence counseling.
5,6
 In a recent report [K Muessig et al., AIDS,  in press] of 
13 studies assessing ART efficacy for preventing HIV transmission in discordant couples, only 
two, from Uganda
7
 and Henan Province, China
8
, found no protective effect. The cohort in Henan 
arises from a well-studied population of HIV patients who were the earliest recipients of ART 
through China’s free public sector treatment program. The comparatively long and ongoing 
follow-up of these Henan couples provides useful insight in to factors dictating the effectiveness 
of ART for prevention in resource poor healthcare settings.  
As victims of regional blood selling scandals in the 1990’s—to which an estimated 30 
thousand HIV infections have been attributed
9—the Henan couples were among the earliest 
recipients of a government administered free ART program to treat all HIV/AIDS patients 
regardless of infection route.
10
 What began as a pilot program among 100 patients in Henan was 
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rapidly scaled up to a nationwide network treating over 52,000 patients by 2008. The 
program today is notable for its size and scale – about 78.5% of the estimated population of 
eligible patients are currently on treatment, and for its success – mortality rates among treated 
patients have fallen from 39.3 to 14.2 deaths per 100 person years from 2000 to 2009.
11
 
Success of the Chinese ART program has been largely attributed its use of the existing 
three-tiered healthcare infrastructure (healthcare centers at village, town, and county levels) 
which allows uniform HIV care to be dispensed even to remote rural commuinties.
12
 To adapt 
the existing system to HIV care needs, health authorities have designated a subset of healthcare 
entities to specialize in HIV care based on geographic distribution of patients in each county. 
Under this system, antiretroviral drugs (and after 2005, relevant laboratory tests and treatment 
for opportunistic infections) are provided free of charge to patients only at their designated HIV 
care clinics—which could be a village, town, or county level care center (Table 5.1)—and those 
seeking care outside the referral chain must bear medical costs themselves. The resulting model 
has successfully lowered AIDs related mortality rates across China, but results presented in 
Chapter 6 indicate that efficacy ART for HIV prevention in places like Henan may have been 
less effective during earlier years of program scale-up. Our  hypothesis that characteristics of the 
healthcare delivery system may affect protective efficacy of ART, is informed by findings from 
our qualitative sub-study presented in Chapter 2, as well as from past studies identifying tier of 
HIV care clinic as a salient predictor of virological failure
13
 and development of drug 
resistance.
14
 
To explore the impact of specific factors on ART protectiveness in rural China, we used 
locally collected data of the Henan couples whose infected (or index) partners received ART 
between 2006 and 2012.  Additional information about the local healthcare system was included 
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to complete the assessment of features of the China’s rural ART delivery system on risk of HIV 
transmission.  
 
Methods 
Data Sources 
Since 2006, disease control centers in the ten counties that make up our study prefecture 
in Henan province have followed a cumulative total of 5285 HIV patients and their uninfected 
spouses to monitor HIV transmission. Eligible couples meet the following criteria:1) registered 
residents living in the study prefecture, 2) over 16 years of age (the age of legal consent in 
China), 3) in a stable marriage (no separation or divorce), 4) one partner confirmed to be HIV 
seropositive and the other seronegative, and 5) willing to provide informed consent. HIV status 
of both partners is confirmed at enrollment through enzyme-linked immunosorbent assay 
(ELISA, Lizhu, Zhuhai, Guangdong Province; Xinzhuang, Xiamen, Fujian Province) conducted 
by county-level CDC’s, and positive test results are confirmed by western blot assay (Ou’ya, 
Hangzhou, Zhejiang Province) carried out at the prefectural CDC laboratories.   
Cohort enrollees were contacted annually to participate in individual face-to-face 
interviews. Trained staff from county disease control centers interviewed partners in their native 
dialect to collect information on demographic characteristics and HIV related risk factors 
including sexual behaviors within and without the primary partnership, history of STIs and 
activities related to blood exchange such as injection drug use or blood donation or transfusion. 
At each survey, initially infected (or index) partners were tested for CD4 cell count and viral 
load and they provided updated information on ART treatment history and new incidents of 
opportunistic infection.  
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Exposure, Outcome and Other Covariates  
We assessed two primary factors of interest: median clinician patient load at each clinic, 
and distance from couples’ villages to their designated HIV care center. Patient load was 
calculated using additional information on HIV care centers provided by county level health 
officials, including tier of each HIV care center, numbers of medical staff, and numbers of 
treated and untreated HIV/AIDs patients, all as of 2012(Table 5.2). 
Distance from patients’ village of residence to their designated HIV care center was 
determined using patient addresses found in the serodiscordant couple database (or if missing, 
from the national epidemiology or treatment databases) and addresses of designated HIV care 
clinics extracted from clinic rosters provided by county health officials. Baidu maps geomapping 
software (http://map.yanue.net/) was used to generate estimates of latitude and longitude of each 
patient’s designated HIV care center and the geometric midpoint of his or her village of 
residence, from which Euclidean distance in km was calculated using the “GEODIST” function 
in SAS 9.3 (SAS Institute, Cary, North Carolina, USA). Optimal coding of both exposure 
variables was based on visual inspection of plots of these values against HIV transmission risk 
and comparing relative model fit using the Akaike information criterion. In addition, field notes 
from our qualitative sub-study indicated that most participants in our study area had access to 
some mode of transportation (whether an electric bicycle, car, or public bus), suggesting that 
distances over 10 km might be far enough away to incur a more substantive effort to reach the 
healthcare settings. The primary outcome of interest was HIV transmission, assessed through 
annual HIV antibody screening for initially uninfected partners. Those who screened positive 
were contacted for confirmatory testing, post-test counseling, and evaluation for treatment 
eligibility.  
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Statistical Analyses 
Couples included in our analysis were those with at least two study visits between 2006 
and 2012, and whose index partner was exposed to ART. We excluded couples whose index 
partners were already exposed to ART before study enrollment to eliminate bias induced by 
under-ascertainment of events that tend to occur earlier in therapy (due to factors such as 
incomplete viral suppression in inexperienced ART users) and from the inability to control for 
baseline factors (such as CD4) that are themselves affected by the treatment.
15
 
Couples experiencing the outcome were censored in the interval in which the 
seroconversion occurred; those who remained discordant throughout the study were censored on 
the date of their last HIV negative test date. Outcomes were validated by comparing our results 
with those in the national HIV surveillance database using a unique identifier or when missing, a 
combination of name, date of birth, and residential address. When results diverged across 
database, preference was given to details in the national surveillance database. Seroconversion 
date was calculated as the midpoint between the date of the last HIV-negative or indeterminate 
test, and three months before the date of the first positive-HIV test, to provide an average 
window period for seroconversion. 
For variables missing information for more than 20% of the sample on any given study 
year, we used Markov Chain Monte Carlo simulation to impute the missing data, and results 
from five imputations were combined using Rubin’s formula.16  
Hazard ratios to assess impact of healthcare access indicators on HIV transmission risk 
were estimated using Cox proportional hazards models. Plots of the hazards over time stratified 
by distance subgroups were examined to assess proportionality of hazards over time, and an 
interaction term with time was assessed using a likelihood ratio test. We used directed acyclic 
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graphs to identify the minimally sufficient of potential confounders of the association between 
healthcare exposures and HIV transmission.
17
  Statistical analyses was conducted using SAS 9.3 
(SAS Institute, Cary, North Carolina, USA) 
 
Ethical Approval 
All data used for this analysis were collected as part of Zhumadian CDC local disease 
control efforts. Ethical approval for the analysis of this data for research purposes was provided 
by the Institutional Review Board of the National Center for AIDS/STD Control and Prevention 
(NCAIDS) at the Chinese Center for Disease Control and Prevention. The current analysis relied 
on an agreement between the Institutional Review Boards of NCAIDS and the University of 
North Carolina, Chapel Hill.  
 
Results  
Overall, 3939 treated HIV patients and their spouses contributed a total of 22,787 person-
years (Table 5.3). Median age of index partners was 44 years, slightly more than half (55.8%) of 
whom were male. About half (51.3%) of index partners (regardless of sex) reported blood or 
plasma selling as their initial route of HIV infection.  In their first year on therapy, 71.7% of 
index partners with a viral load value achieved viral suppression. 
Overall, 46 HIV transmission events occurred over the course of the study, for an 
incidence rate of 0.20 cases per 100 person years. In unadjusted bivariable analyses, HIV 
transmission rates were higher for couples whose index partners had the following characteristics: 
male sex, infected with HIV through blood/plasma selling (couples missing this information also 
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had higher rates), “farmer” as their primary occupation, and had a designated clinic with a 
greater than 100 patient volume.  
 Clinic tier and distribution varied widely by county (Figure 5.1). Patients lived a median 
distance of 5.3 km from their designated clinic, with most (85.1%) living within 10 km and a 
small minority (N=89) living over 25 km away. In most cases, index partners were assigned to 
village level HIV care centers  (63.4%); the remainder was assigned to township health centers 
(34.7%) or county hospitals (2.0%). Village clinics tended to have a higher median number of 
patients than township health centers (45 versus 22) and slightly higher patient burden (13.8 
patients per clinician versus 7.3, respectively; Table 5.3). Only one county hospital operated as a 
designated HIV care site to 178 patients from our study. The large staff size of this entity (6 
physicians and 9 nurses) meant that its patient burden of 11.9 patients per clinician was 
comparable to other tiers of healthcare. 
 
Effects of Patient Volume of HIV Care Center on HIV Transmission 
 Unadjusted models of the effect of patient volume of HIV care centers on HIV 
transmission risk showed that couples assigned to HIV care centers with more than 100 patients 
per clinician had 60% higher risk of transmission (HR=1.59, 95% CI 1.01-2.49) compared to 
those at centers with lower patient volume. The effect was preserved when potential confounders 
were included in the model, though adjustment moderated the effect towards the null (HR=1.24, 
95% CI, 0.76-2.03). Mean time to HIV transmission among those assigned to clinics with high 
patient volume  was shorter than for those at town or county HIV care centers (3.1 versus 3.7 
years; Table 5.5).  
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When stratified by tier of care center, in unadjusted models patient volume per clinician 
more than doubled risk of HIV transmission in those assigned to village care centers (HR=2.20, 
95% CI, 1.25-3.87), an effect that was only slightly changed by adjustment for confounders 
(HR=2.26, 95% CI, 1.27-4.03). The effect among those assigned to town or county level clinics 
was too imprecise to ascertain an effect, given the low case count in this subgroup (HR=0.66, 95% 
CI, 0.04-11.23).  
 
Effects of Distance from HIV Care Center on HIV Transmission 
In unadjusted Cox models, living more than 10km from a designated HIV care site was 
associated with lower HIV transmission risk (HR=0.56, 95% CI, 027-1.17). This relationship 
changed little after adjustment for potential confounders (HR=0.52, 95% CI, 0.22-1.22). Mean 
time to HIV transmission was shorter among those living farther than 10km from their 
designated clinic (3.2 versus 4.2 years for those living ≤10km), and was shorter among couples 
assigned to HIV care at village clinics (3.3 versus 4.2 years for those assigned to town or county 
level centers; Table 5.5). 
Stratification of these unadjusted estimates resulted in divergent patterns across tiers of 
care. Among those assigned to town or county level HIV care centers, farther distance was 
associated with lower HIV transmission risk (HR=0.50, 95% CI, 0.15-1.69), whereas this same 
risk was elevated among those assigned to village care centers (HR=1.18, 95% CI, 0.44-3.15). 
Adjusted models produced results mirroring those of unadjusted stratified analyses with higher 
risk for those living farther from their designated village care centers (HR=1.22, 95% CI, 0.46-
3.27) and lower risk for living father from town or county care centers (HR=0.18, 95% CI, 0.02-
1.36). Estimates of the effect of distance on HIV transmission were all highly imprecise.  
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Discussion  
We observed that higher patient volume was strongly associated with elevated risk of 
HIV transmission in our population. When stratified, this effect was magnified among couples 
assigned to village level HIV care centers but no association could be found for those at town 
and county centers. The relationship between distance to HIV care center and HIV transmission 
risk was less pronounced but may have varied by tier of HIV care center.  
The relationship between our two exposures—travel distance and patient load—and HIV 
transmission risk are linked in our study by way of the reinforcing role of routine healthcare 
access on suppressive capacity of ART. Regular access to quality healthcare can help treated 
HIV patients sustain viral suppression through greater exposure to adherence counseling, earlier 
identification of virological failure, and maintenance of optimal drug regimens. Though 
behavioral factors such as frequency of sex or condom use also predict HIV transmission, these 
behaviors are not thought to be associated with how far patients live from their HIV care centers, 
nor with any features distance of those centers, suggesting that suppressive capacity—rather than 
risk behaviors—better explain observed differences in HIV transmission rates across subgroups. 
Moreover, using the very limited viral load data available, we found that median viral loads in 
the first year of ART exposure were higher for those assigned to village (470 copies/µL) than 
those at town or county care centers (50 copies/mL), further supporting our hypothesized 
pathways. Interpretations regarding viral load data should be interpreted with caution given the 
high and nonrandom missingness of the original data before imputation. 
 Strong associations between higher patient volume and risk of HIV transmission suggest 
that adequate visit time with clinicians and clinic resources may play an important role in helping 
patients sustain viral suppression. This was particularly the case in village HIV care centers 
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where patient load is generally higher (Table 5.2) and where laboratory monitoring services can 
only be accessed by shipping samples to higher tiers of care.  The impact of patient-provider 
relationships on patient satisfaction and improved medication adherence are well known.
18
 In 
addition, a survey of Chinese HIV care providers has found that those perceiving strong 
institutional support from their workplace–in the form of things like HIV related medical 
trainings or prophylactic equipment to minimize occupational HIV exposure—have less 
discriminatory attitudes towards their HIV infected patients.
19
 Our finding that higher patient 
volume increased risk of HIV transmission in village level HIV care centers suggests that 
targeting new resources to lower-tier sites strained by large patient numbers may yield high 
marginal returns in the form of reduced HIV transmission.  
That distance to clinic was a less salient predictor of HIV transmission may not be 
surprising in light mixed findings from past studies.
20-22
 However, the fact that stratified 
estimates of this effect moved estimates to opposite sides of the null value suggests that the 
underlying mechanism linking distance and routine medical care may differ by the type of 
healthcare center. Past research has found that among rural Chinese patients, concerns about 
provider expertise and reputation drive choice of provider more than barriers imposed by cost of 
care or travel distance to a specific clinic.
23,24
 Among Chinese HIV patients specifically, views 
on physician expertise and quality of clinics have both been linked to patient satisfaction and 
medication adherence.
25
 Patients’ faith in their own healthcare system may therefore alter 
minimum thresholds of distances they may be willing to travel for this care. Though we did not 
directly measure perceptions of care quality in our participants, less favorable impressions of 
village clinics would not be surprising given the marked contrasts in available resources found at 
these sites (Table 5.1).  
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Though still preliminary, findings from this analysis support several modest 
recommendations. First,  interventions to ease the work burden of clinicians at HIV care centers 
with high patient load—particularly at lower tier care centers—could have an immediate and 
disproportionate impact on treatment outcomes and transmission risk among patients at these 
centers. Low cost interventions might include adherence counseling programs administered by 
non-physician staff,
24
 or uptake of technological innovations such as point of care viral load 
testing, could have a substantial benefit for enhancing both the therapeutic and preventive effects 
of HIV.
27,28
 Second, since perceived quality may be a stronger motivator than proximity in terms 
of care seeking, cost effective ways to alter patient perceptions of care quality and clinicians 
competence may not improve patient willingness to seek more routine care, but also 
substantively improve quality of care they receive.
25
 Concentrating financial resources into a 
subset of sites may be politically difficult in the short term, but initiatives such routine field visits 
by respected HIV physicians or regular trainings for village clinicians could signal stronger 
intent on the part of health officials to close gaps in health disparities. Last, the three-tier rural 
healthcare system through which the Chinese government delivers ART was optimized for an era 
of highly restricted mobility in rural populations.
29
 Today, migration among China’s rural 
population is the most extensive documented in human history;
30
 as such, an ART delivery 
system capable of centralized, real-time reporting could enhance case management and 
streamline drug supply chain management.  
Results of this analysis must be interpreted in the context of China’s unique healthcare 
delivery model; however insights into drivers and barriers of routine medical care among HIV 
patients are widely applicable to many HIV affected populations globally. Our choice of 
Euclidean distances is an improvement upon self-reported measures;
22
 however, a validation of 
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our geomapping software measures against manually inputting start- and end-addresses found 
that our measure may slightly overestimate these distances. 
The success of China’s decentralized HIV care model to rapidly expand coverage and 
reduce mortality in resource limited settings is nothing short of remarkable.
31
 Task-shifting and 
decentralization has long been advocated by the WHO,
32,33
 for rapid roll out of HIV care in 
resource limited settings. Direct generalizations of guidelines from wealthier settings in places 
with far fewer resources,
5
 however, may require more careful exploration of how features of 
local healthcare systems may facilitate translation of this evidence into practice.  
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Tables and Figures 
 
Table 5.1. Characteristics of  the healthcare system in study prefecture 
  Village clinic Township health center County hospital 
Services Basic health services 
including physical 
examination and drug 
dispensation by non-
physicians. 
Primary healthcare and 
supervision of village clinics. 
Full time pharmacists. 
Larger medical center with 
referral and specialty services. 
Full time pharmacists 
Medical Staff One full-time or several 
part-time nonphysician 
clinicians. 
Several full time physicians.  Full time physician clinicians; 
usually staffed within an 
infectious disease ward. 
Laboratory 
testing capacity 
No on site laboratory; lab 
samples are transported to 
higher level laboratories 
for testing. 
Some CD4 cell count testing 
capacity.  
Full CD4 and VL monitoring 
capacity. 
 
 
Caption: Table 5.1: Descriptions of the three tiers of healthcare entities providing HIV care in the 
study prefecture. 
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Table 5.2. Characteristics of each tier of HIV care centers in the study prefecture 
  Village clinic Township health center County hospital 
Total number in Zhumadian 91 75 1 
Treated patients per clinic (median) 45 22 178 
Medical staff per clinic (median) 3 3 15 
Patients per clinician (ratio) 13.8 7.3 11.9 
 
Caption: Table 5.2: Statistics of the three tiers of healthcare entities providing HIV care in the 
study prefecture. 
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Table 5.3. Characteristics of the 3939 HIV serodiscordant couples included in the final 
analysis 
  
HIV 
Transmission N 
(%) 
No HIV 
Transmission 
N(%) 
PY 
Cases per 100PY 
(95% CI) 
Total 46 (1.2) 3893 (98.8) 22787  0.20 (0.15-0.27) 
Sex of index partner--N(%) 
       
 
Female 16 (0.9) 1726 (99.1) 10109 0.16 (0.10-0.26) 
 
Male 30 (1.4) 2167 (98.6) 12678 0.24 (0.17-0.34) 
Age of index partner--N(%) 
      
 
 
<45 19 (0.9) 2038 (99.1) 12110 0.16 (0.10-0.25) 
 
≥45 27 (1.4) 1855 (98.6) 10677 0.25 (0.17-0.37) 
Index partner HIV transmission route--N(%) 
     
 
Blood/plasma donation 38 (1.9) 1983 (98.1) 11251 0.34 (0.25-0.46) 
 
Blood transfusion 1 (0.2) 605 (99.3) 3657 0.03 (0.00-0.19) 
 
Injection drug use 0 (0) 76 (100) 492 0.00 -- 
 
Sexual contact 1 (0.0) 1080 (99.9) 6454 0.02 (0.00-0.11) 
 
Missing 6 (3.9) 149 (96.1) 933 0.64 (0.29-1.43) 
Index partner occupation--N(%) 
       
 
Farmer 45 (1.2) 3582 (98.8) 20989 0.21 (0.16-0.29) 
 
Non-farmer 1 (0.3) 311 (99.7) 1798 0.06 (0.01-0.39) 
Clinic Tier--N(%)   
   
  
 
Village  38 (1.6) 2273 (98.4) 12890 0.29 (0.21-0.40) 
 
Township  6 (0.4) 1359 (99.6) 8275 0.07 (0.03-0.16) 
 
County  0 (0) 75 (100) 441 0.00 -- 
 
Missing 2 (1.1) 186 (98.9) 1181 0.17 (0.04-0.68) 
Distance from designated clinic 
       
 
≤10 km 43 (1.3) 3311 (98.7) 19361 0.22 (0.16-0.30) 
 
>10km 3 (0.5) 582 (99.5) 3426 0.09 (0.03-0.27) 
Patient volume of designated clinic 
     
 
≤100 patients per clinician 25 (0.9) 2712 (99.1) 15950 0.16 (0.11-0.23) 
 
>100 patients per clinician 18 (1.9) 940 (98.1) 5312 0.34 (0.21-0.54) 
 
Missing 3 (1.2) 241 (98.7) 1525 0.20 (0.06-0.61) 
Index partner baseline CD4--N(%) 
       
 
≤250 cells/µL 14 (1.2) 1204 (98.9) 7131 0.20 (0.12-0.33) 
 
>250 cells/µL 32 (1.8) 2689 (98.8) 15656 0.20 (0.14-0.29) 
 
Caption: Table 5.2: PY, person years. CI, confidence intervals. 
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Table 5.4. Hazard ratios comparing HIV transmission risk in serodiscordant couples by 
distance to, and patient load of, HIV care center 
Effect of patient load per clinician at designated clinic on HIV transmission risk 
    
Unadjusted HR       
(95% CI)  
Adjusted HR*               
(95% CI) 
Overall  
     
 
>100 patients 1.59 (1.01-2.49)  1.24 (0.76-2.03) 
 
≤100 patients 1.00 -- 
 
1.00 -- 
Village tier HIV care center**      
 
>100 patients 2.20 (1.25-3.87) 
 
2.26 (1.27-4.03) 
 
≤100 patients 1.00 -- 
 
1.00 -- 
Town or county tier HIV care center**     
 
>100 patients 0.68 (0.04-11.64) 
 
0.66 (0.04-11.23) 
  ≤100 patients 1.00 --   1.00   
 
Effect of distance in km to designated clinic on HIV transmission risk  
    
Unadjusted HR       
(95% CI)  
Adjusted HR*               
(95% CI) 
Overall  
   
  
 
>10km 0.56 (0.27-1.17) 
 
0.52 (0.22-1.22) 
 
≤10km 1.00 -- 
 
1.00 -- 
Village tier HIV care center**      
 
>10km 1.18 (0.44-3.15) 
 
1.22 (0.46-3.27) 
 
≤10km 1.00 -- 
 
1.00 -- 
Town or county tier HIV care center**     
 
>10km 0.50 (0.15-1.69) 
 
0.18 (0.02-1.36) 
  ≤10km 1.00 --   1.00   
 
Caption: Table 5.4: HR, hazard ratio. CI, confidence interval. *Adjusted models included 
variables for clinic type, distance from clinic (if not already included as the exposure), patient 
volume (if not already included as the exposure), age, sex, and occupation. *Stratified analyses 
show results of the unadjusted and adjusted models using interaction terms for clinic type 
(village level vs. town or county level) 
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Table 5.5. Mean time to HIV transmission among serodiscordant couples 
Subgroup 
Mean time to HIV 
transmission 
Clinic tier 
 
 
Village 3.24 
 
Town or county 4.22 
Distance from clinic 
 
 
>10km 3.44 
 
≤10km 4.75 
Patient volume per clinician 
 
>100 patients 3.10 
  ≤100 patients 3.67 
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Figure 5.1. Distribution of HIV care centers and median distance by county in study prefecture  
 
 
Caption: Figure 5.1: Counts of each tier or AIDS care clinic and median distance from patient 
homes to clinic are indicated for each county. Number of people living with HIV/AIDS per 
10,000 population in 2012 is indicated by the shaded color of each county. 
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CHAPTER 6: DISCUSSION 
The primary goal of this dissertation was to estimate the protective effect of ART on HIV 
transmission risk in serodiscordant couples. This research was motivated both by the need for 
better insight into effectiveness of suppressive ART in real world settings, as well as to resolve a 
puzzling set of results from two past analyses of this study population.
1,2
 Our secondary goal was 
to assess the relationship between systems-level mechanisms of ART delivery and HIV 
transmission risk in this population.  
 
Aim 1: ART to prevent HIV transmission 
 Our study identified a protective effect of ART on HIV transmission in serodiscordant 
couples in Henan, China from 2006 to 2012 (HR, 0.55) after adjustment and weighting for time-
varying confounding. This effect was stronger than that of Study 1 which had reported no 
protective effect between 2006 and 2008 (HR, 0.76),
1
 but was less in magnitude than the effect 
reported in the subsequent Study 2 from 2007 to 2011 (HR, 0.05).
2
 While varying 
methodological approaches likely explain some of these differences, a key finding of this 
dissertation was the time-varying nature of ART efficacy in this population. This confirms that 
the protective effect of ART was likely nonexistent in early years of the program, after which a 
strong protective effect took hold in about 2009, thereby corroborating the effects reported by 
Study 1 and 2. That 2009 coincides with the beginning of systemization of China’s ART 
administrative program structure, massive scale-up of resources including for laboratory 
monitoring, and introduction of free second line therapies is likely not a coincidence. The time-
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varying nature of ART efficacy is not only substantively meaningful, but also highlight the 
futility of interpreting summary hazard ratios given their tendency to average over time-varying 
effects, thus masking changes along the way. Hazard ratios may also over-represent the 
experiences of persons who survive until the end of the study.
3
  
Findings from this dissertation contribute to an ongoing investigation of treatment as 
prevention in Chinese settings (Table 6.1). A national database-driven analysis of over 38,000 
couples in China,
4
 for example, has found that ART efficacy was lower in former blood plasma 
donors relative to other groups, further supporting our hypothesis that early ART in Henan was 
fundamentally different than the standardized care that was rolled out in Henan and nationwide 
by 2009. Contrasts of our study estimates with other serodiscordant couples studies in China are 
best considered alongside a comparison with methodological differences across studies. 
 Limitations of Aim 1 are can guide interpretation and generalization of these results. 
Primary among these is our assumption that all HIV infections in non-index partners were 
acquired within the primary partnership. Sociological and epidemiological data on rural Chinese 
populations
5
 and former plasma donors
6
 suggest that this is not an unreasonable assumption, but 
the ideal method of verification through phylogenetic linkage of paired viral samples was 
hindered by availability of useable stored plasma samples.  
 Another limitation was the high and nonrandom missingness of viral load data. Though 
the biologic pathway from ART to sexual HIV transmission in sexual partners is presumed to 
pass through viral suppression, an explicit effort to verify its role as the primary indicator of 
transmissive potential would have strengthened our findings. Such data could have also 
potentially identified predictors of high risk subgroups in the absence of transmission events. 
Although our multiple imputation of this variable accounted for the time dependence and prior 
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information about data distribution, problems with the original data undermined veracity and 
interpretability of in-depth analyses using imputed viral load data. 
 The primary strength of this analysis was our ability to assess HIV transmission events, 
made possible by the participation of serodiscordant couples. By being able to assess risk factors 
for both transmission and acquisition, this study design provided insight into a logistically 
challenging—yet epidemiologically meaningful —type of outcome. Our analysis also benefitted 
from validation of both outcome and exposure data with national level databases. Since local 
clinicians and disease control staff face high administrative burdens in reporting case information 
to multiple entities, health experts at the national center for disease control verified cases by 
phone and routine site visits. By comparing our data to records stored in the national database, 
this analysis minimized potential bias from misclassification error. Our restriction of analysis to 
new users of ART also helped establish a clear temporality between baseline confounding 
variables, ART use, and transmission. Finally, our use of marginal structural models to address 
time-varying confounding by variables that were also affected by prior exposure, helped address 
this source of confounding common to longitudinal observation of pharmacologic effects.  
 
Aim 2: Distance and Patient Volume on HIV Transmission   
 Estimates obtained for our second aim showed that higher patient load per clinician at 
HIV care centers was associated with elevated risk of HIV transmission among treated couples in 
our population, particularly at village level centers. Adequate time with clinicians and 
availability of clinic resources may play an important role in helping patients sustain long term 
suppression. The association between distance to clinic and HIV transmission risk was far less 
consistent, though we may have detected a possible elevation of risk associated with living father 
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from village level HIV care centers but a lower risk among those living far from town or county 
level centers. Though it is possible that patient perceptions of care quality may alter their 
willingness to travel for this care, the lack of precision limits interpretability of these results. 
 The primary limitation of our second aim was the validity of our assumption that distance 
from a patient’s home to his or her designated HIV care center was representative of distance to 
care centers where care was actually sought. Though most participants in our study reported 
being farmers—a population with per capita income of 5000RMB or about 600 US dollars in 
2013—and are therefore less likely to be able to afford fee based care at non-designated clinics, a 
few may still opt to attend other care centers where they feel care quality is better or where they 
can avoid inadvertent HIV status disclosure in their local communities. In addition although our 
study prefecture is set in a flat plains region and where communities are connected by a modern 
network of paved roads and highways, we were not able to account for the presence of two large 
reservoirs in our distance calculations and thus may have underestimated actual distances for 
participants who traveled farther to circumnavigate these bodies of water in real life.    
Our lack of other information on patients’ health seeking behaviors or on salient details 
of healthcare centers also limited our inability to develop a more nuanced view of the interplay 
between good access and reliable quality of healthcare. 
Our inability to assess impact of our exposure on useable viral load data was for reasons 
similar to those described above for Aim 1. 
 
Future Directions for Public Health Policy 
Intense interest has mounted over the potential for HIV treatment as prevention to slow 
and eventually stop the HIV epidemic.
7
  Enthusiasm for this strategy has been attributed not only 
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to the unprecedented success of HPTN 052
8
 relative to other large scale HIV prevention trials, 
but also to lags in vaccine development,
9
 collective frustration at the futility of existing 
behavioral interventions
10
 and the broader availability of increasingly tolerable and inexpensive 
drugs even in the developing world.
11
 The promise of this tool, however, is not without 
substantial risks and tradeoffs. With scale-up to treat more and individuals at higher CD4 cell 
counts may come concomitant rise of drug resistant HIV strains, as increasingly healthy 
individuals will be referred to ART among whom adherence may not be strong. The potential for 
improved ART access to stimulate riskier sexual behaviors, a phenomenon known as risk 
compensation, has already been documented in some populations with high ART coverage.
12
 
Effective “treatment as prevention” strategies will also need to consider the disproportionate 
contribution of acutely infected individuals to onward transmission, given their elevated potential 
for transmission and inherent difficulty in identifying these individuals.
13
  
Research to inform effective, cost efficient, and locally acceptable implementation of 
treatment for prevention that are well suited for resource constrained environments is underway 
in the form of several large scale community randomized trials.
14
 However, policy may be 
outpacing the evidence that can be provided by such slow-moving and expensive trials. One goal 
of this dissertation is to close the gap between science and policy by harnessing observational 
data to assess effectiveness of ART for preventing HIV transmission in real world settings.   
Findings from this study underscore the fact that ART is a potentially powerful but 
imperfect tool for HIV prevention. ART programs in resource poor areas may have an immediate 
impact on HIV mortality, but may not immediately be able to achieve the population-level 
protective benefits cited in developed settings.
15,16
 Combination implementation to sustain 
multifaceted strategies that harness biomedical and behavioral interventions
17
 must therefore 
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continue to be advanced up lists of priority policies. With these limitations in mind, however, 
methods to harmonize therapeutic and preventive goals of suppressive ART may have multiplier 
benefits across the system. Phasing out CD4 testing in favor or more frequent virological testing, 
for example (current protocol in China and other resource poor settings dictates a single annual 
viral load test), might be considered in not in spite of, but rather because of, the high costs and 
labor intensiveness associated with the test. Concentrating available resources in the gathering of 
viral load data can help clinicians with few other means more reliability identify patients who are 
failing therapy and provide them with immediate assistance whether in the form of more 
counseling to resuppress or by altering their drug regimen. It could also function as a counseling 
aid for unsuppressed patients to prioritize adherence or consider condom use in order to protect 
their sexual partners.  
Long term suppressive ART is borne out of a partnership between patients and their 
healthcare systems. Quality of healthcare therefore matters greatly, as does patients’ trust in their 
healthcare system. Initiatives to improve perceptions can improve patient satisfaction and with it, 
health outcomes.  Incorporation of patient feedback regarding barriers to care may improve 
delivery while empowering patients to advocate for their needs as patients. 
 
Future Directions for Research 
One critical question remaining after this research is about prevalence of unlinked 
transmission in Chinese serodiscordant couples. To date only one study in China has assessed 
phylogenetic similarity in viral samples from seroconverting couples, among whom all events 
were linked.
18
 Several more data points would deepen understanding of behaviors in Chinese 
couples and better inform future couple-based intervention strategies. This information will also 
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provide much needed inputs to form key parameters for mathematical models estimating 
treatment as prevention impact.  
Another area for further research is documentation of healthcare service and delivery 
indicators. Routine data gathering of resources expended in healthcare services can be paired 
with information about virological failure or drug resistance, two outcomes linked to low 
healthcare quality in past studies
19,20
 could better characterize not only ways to prevent new 
infections but also patterns and key subgroups that drive population level spread of HIV. Two 
key parameters identified by this dissertation that can measure healthcare system’s abilities to 
deliver effective ART for prevention include patient perceptions of care quality and the nature of 
interactions between patients and physicians. 
Finally, future comparisons of ART efficacy in the real world must account for the high 
probability that underlying risks may vary over time. Large scale shifts in treatment 
environments are to be expected, particularly in settings like China that are undoing rapid social 
and economic change. Summary hazard ratios may be useful as a cursory tool for comparison 
across studies, but we recommend additional methods to present results including adjusted 
survival curves
21
 or supplementary statistics from flexible parametric alternatives to Cox 
model.
22
 
 
Summary  
 Widespread access to ART and HIV testing in China make it an ideal candidate for 
controlling the HIV epidemic through population level ART. Its ability to establish an ART 
treatment environment in even the most rural and resource constrained areas bode well for 
treatment as prevention in the developing world. However the protective effect was neither 
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constant nor perfect, and was itself closely linked to other features of the how the healthcare was 
delivered. Findings from this research hope to inform initiatives of Chinese health officials who 
have already taken decisive steps towards national roll-out of a treatment program whose 
primary goal is HIV prevention .
23
 Moreover China’s experience can provide timely insight and 
guidance for other resource constrained communities that are also weighing strategies to mitigate 
the effects of HIV in their populations. 
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Table 6.1. Comparison of serodiscordant couple studies on treatment as prevention in China  
Author 
[year] 
Time 
Period 
Study Design Results Conclusion 
Wang Lu 
(2010)
1
 
2006-
2008 
Zhumadian CDC 
serodiscordant couple cohort. 
N = 1927 couples. 
Overall incidence: 1.17/100PY. Crude 
estimate for effect of ART on HIV in negative 
partner: HR= 0.76 (95% CI,  0.45-1.28). 
ART did not prevent HIV 
seroconversion in negative partners. 
Wang Lan 
(2013)
2
 
2007-
2011 
Zhumadian CDC 
serodiscordant couple cohort. 
N = 4499 couples. 
Overall incidence: 0.82/100PY. Crude 
estimate for effect of ART on HIV in negative 
partner: HR=0.36 (95% CI,  0.24-0.55). 
Adjusted estimate: 0.05 (95% CI, 0.01-0.16)* 
ART exposure was highly protective 
against HIV seroconversion in negative 
partners. Durability of ART protective 
benefit wanes after 7 years. 
He N 
(2013)
18
 
2009-
2011 
Dehong, Yunnan 
serodiscordant couple cohort. 
N = 813. 48% of index cases 
were IDU, virological 
linkage confirmed for all 
seroconversions 
Overall incidence: 1.5/100PY. Crude estimate 
for effect of ART on HIV in negative partner: 
HR=0.34, 95%CI=0.12-0.97. Adjusted 
estimate: HR=0. 30 (95% CI, 0.10-0.86)** 
ART as associated with a 66% 
reduction in risk of HIV transmission in 
these couples. 
Jia Z 
(2013)
4
 
2003-
2011 
Retrospective cohort 
assembled from national 
epidemiology and treatment 
databases. N = 38,863. 
Overall incidence: 2.6/100PY. Crude estimate 
for effect of ART on HIV in negative partner: 
HR=0.61, 95%CI=0.55-0.67. Adjusted 
estimate: HR=0. 74 (95% CI, 0.65-0.84)*** 
Stratified by transmission route find FPDs HR 
= 0.91, (95% CI, 0.72-1.14) 
ART exposure was highly protective 
against HIV seroconversion in negative 
partners. Durability of ART protective 
benefit wanes after 4 years. 
Caption: Table 4.4: *Adjusted for duration of follow-up, sex, age, education, marital status, occupation, route of HIV infection, 
and baseline CD4 cell count of the index patient; ** Adjusted for education, sexual frequency, condom use, last recorded CD4 
cell count, AIDS diagnosis, last recorded viral load, and ever being exposed to ART; *** Adjustment for age, sex, education, 
seropositivity for herpes simplex virus 2, and frequency of sex.  
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APPENDIX 1. Neighbor Joining Tree 
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Caption: Appendix 1: Neighbor joining tree documenting 10 transmission events based on an 
analysis of gag sequences from index-partner pairs (marked with colored dots).  The tree also 
includes 17 subtype-matched reference sequences (ZK--, CBJ--, B.CN--) and 6 local controls 
(gag-HA110007, --17, --21, --22, -38, --40). Bootstrap values are shown for the grouping of 
index and partner sequences for each event based on 500 bootstrap replications. 
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APPENDIX 2. Maximum likelihood tree 
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Caption: Appendix 2: Maximum likelihood tree documenting 10 transmission events based on an 
analysis of gag sequences from index-partner pairs from Zhumadian (marked with colored dots).  
The tree also includes 17 subtype-matched reference sequences (ZK--, CBJ--, B.CN--) and 6 
local controls (gag-HA110007, --17, --21, --22, -38, --40). Bootstrap values are shown for the 
grouping of index and partner sequences for each event based on 500 bootstrap replications. 
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APPENDIX 3. Patient Interview Guide 
 
Date of Interview: ___________________ 
Location of Interview: ________________ 
Interviewee ID #: ____________________ 
Section 1. Obtain information about the diagnosis experience, changes in transmission related risk 
behaviors since diagnosis, and treatment experience. 
Warm Up Questions 
 How many people are in your family? 
 How did your family come to live in this town?  
 How do you and your family make a living? 
 Can you tell me about your experience participating in the discordant couple study? 
 How long have you been taking part in the study? 
 
HIV Related History 
 Were you already diagnosed with HIV before the study began?  
 Can you tell me more a bit more about the first time you were diagnosed?  
 Where and by whom were you diagnosed?  
 What do you remember discussing with your doctor/provider at the time? 
 Can you describe the process by which your partner learned about your results?  
 
Post Diagnosis  
 Some couples experience a change in their sexual behaviors after one of them learns that he/she is 
HIV positive. How would say your sexual behaviors have changed since learning your status? 
 How have your feelings about sex changed if at all? 
 How has the frequency of sex with your partner changed, if at all? 
 Can you talk about any changes that you and your partner made to your sex life to avoid possible 
HIV infection?  
 Can you describe any prevention methods that are commonly recommended for couples in your 
situation?  
 Some couples have difficulty using these methods every time they have sex. Can you think of any 
reasons why they have trouble? [If appropriate, can ask if participant has ever personally 
experienced any of these difficulties] 
 
Treatment History 
 Can you tell me about your experience on HIV treatment? 
 How did you decide to start treatment?  
 What do you remember discussing with your doctor about treatment? 
 Can you describe your ART regimen? (Names of drugs, doses, etc.) 
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Section 2. Goal is to solicit as many barriers to treatment success as possible with the following statement, 
then follow-up on any mentioned items with the probes below.  
"We know that people who are HIV infected can live longer, healthier lives by keeping the levels of virus 
in their body as low as possible.  Usually this is achieved by adhering to medication every day. But there 
are many reasons why this might be difficult for people. Some examples include the difficulty of 
remembering to take one’s medicine every day, or the fact that the drugs sometimes have uncomfortable 
side effects. What are some example of things that you think can make it difficult for people to adhere to 
their medicines?" 
 
1. Individual Level: Memory, Routine, etc. 
Any mention of forgetting, losing track of schedule, disruptions to routine, etc 
 Can you tell me more about why you have trouble remembering to take your medications?  
 Can you tell me about the most recent time you missed a dose?  
 Can you describe your routine in a typical day? Is it difficult to take your medicine at the same 
time each day? 
 What are some ways you think people can overcome some of these barriers? (Prompts: alarm 
clocks, recruiting family members to remind them, coordinating it with another routine like tooth 
brushing, etc. 
 
2. Individual Level: Drug Side Effects 
Any mention of ever having experienced side effects from ART  
 Can you tell me about the worst/most recent side effects you've experienced? What did you do in 
that case?   
 Have you experienced side effects in the past year?   
 Can you describe the conversations you had with your providers about side effects prior to 
starting ART? 
 Have you ever had to stay overnight at a hospital/clinic due to side effects? 
 Does your current regimen (or termination of ART) reflect the changes made as a result of side 
effects?  
 
3. Relationships: Social Support 
Any mention of outside perceptions of the participants or the attitude of people regarding one's HIV 
infection. 
 How many people in your family or among your close friends know your status?  
 In what ways do you think friends and family can help an HIV patient stay healthy and regularly 
take their medicines? 
 In what ways have your family and friends been supportive and helped you maintain good health?  
(Prompts: pick up drugs, accompany to appointments, remind to take drugs) 
 
4. Relationships: Provider Interactions 
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Providers can play an important role in a patient’s long-term health and ability to regularly take their 
medications. Providers can provide helpful information and encourage patients. 
 Can you describe your relationship with your primary HIV care provider? 
 In what ways has he/she/they helped you adhere to your medication (prompts: coaching better 
adherence, effective management of side effects, etc.)? 
 Have you ever had an instance where your doctor wasn’t able to help solve a medical problem 
you had? What happened? How did this affect your relationship? 
 How easy is it for you to meet with your primary doctor, or a doctor who has seen you before? 
 
5. Relationships: Stigma & Social Discrimination 
Sometimes it can be difficult to make sure you have enough medication to ensure that you don’t miss any 
doses. Have you ever had difficulties on this front? 
 Do you think stigma towards HIV patients is a problem in your community?  
 If you have ever experienced stigma or discrimination either in the community or healthcare 
setting, can you describe what happened? 
 What would it mean for you if neighbors & friends learned about your status 
 
6. HC Systems Level: Clinic Access 
 Being able to reach your get to your clinic or pharmacy in a timely manner is very important part of 
staying healthy.  
 Do you have more than one place where you seek medical care? If so, how do you decide which 
HC center you go to?  
 Can you describe any preparations you make to see your doctor (prompts: scheduling 
appointments, arranging transportation, arranging for childcare or missing work, etc.) 
 Can you describe the process of traveling to the HC center, including how long it takes, how 
much it costs, and any other notable things? 
 Have you ever not been able to access care or prescription refills because of the clinic or 
pharmacy hours?  
 Have you ever not been able to fill a prescription because the pharmacy had run out of medication? 
 
7. HC Systems Level: Economic Factors 
Healthcare costs can be  
 How much money do you spend in a month (half year? year?) for your healthcare? 
 How concerned are you about paying for your healthcare?  
 Where does the money for your healthcare come from (prompts: household income, savings, 
borrowing from friends/family, borrowing from bank, etc.) 
 Do you have health insurance? If so, what kind (prompts: public, private)? 
 In your view how much of your medical needs is covered by your health insurance? 
 How has the Four Frees, One Care program affected you and your family? If you could change 
one thing about the program, what would it be? 
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Section 3.  
Research has found that patients who take their medications every day may be less likely to infect their 
partners. But others think that preventing HIV this way can be very difficult. Do you think this method 
would be effective for you and your partner? How about for other couples in this town?  
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APPENDIX 4. Provider Interview Guide 
 
Section 1.  Basic Information 
 
1. Sex [record gender as observed] 
 
2. What is your current age?  
 
3. What is your primary health care center (HCC) of employment? How many other staff work at this 
HCC full time (n = ) and part time (n = )? 
 
4. How long have you worked in the medical profession? What is your specialty? 
 
5. What is your current position, and how long have you served in this position?  
 
6. How did you first become involved in HIV care? 
 
 
Section 2. Training 
 
7. Can you explain any HIV specific medical training you have received?  
Probes: 
 What organization provided the training? 
 How was the training paid for? 
 What skills did you gain at through the training? 
 
8. If you could participate in any sponsored training for HIV providers, what skills would you like to 
develop? (e.g. pharmacology, home based care, behavioral counseling, mental health management, 
surveillance, research, etc.) 
 
 
Section 3. Resources 
 
Please describe any resource constraints you experience in terms of the following:  
 
9. Medical supplies or equipment (e.g. lab supplies, diagnostic tests, hospital beds, emergency 
transportation measures)  
10. Drugs (ART, or for side effects of opportunistic infections) 
11. Support staff (nurses, pharmacologists, psychiatrist/counselors, etc.) 
12. Time: what is your current patient load (i.e. how many patients would currently consider you 
their primary care provider?). Do you feel pressed for time when meeting with your patients? 
 
 
Section 4. Psycho-Social Factors 
 
13. In some places, providers avoid working with HIV positive patients for a number of reasons. 
What are some reasons that some providers might do this? (e.g. fear of getting infected, feel a 
lack of professional qualification, discomfort working with possible sex workers or drug users, 
etc.). Have you ever experienced such feelings in the past? 
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14. In some places providers who work with HIV patients have experienced discrimination by other 
healthcare providers. Have you or anyone you know ever experienced this? 
 
 
Section 5. Treatment Challenges 
 
15. What portion of your treatment eligible patients are currently receiving ART? What do you think 
is the primary reason that the remainder are not on treatment (prompts: fearful of side effects, 
cannot afford the testing, patient doesn’t think it’s necessary, etc.)? 
 
16. What portion of your patients on treatment do you think are currently suppressed? What do you 
think is the primary reason that those who are not cannot achieve suppress (prompts: poor 
adherence, suboptimal regimens, side effects, drug resistance, etc.)? 
 
17. What do you typically discuss when you meet with patients? How often do you have lab 
monitoring (CD4, VL, drug resistance testing) results available? How do you assess a patient’s 
health when you don’t have lab results? 
  
18. HIV patients in other developing areas have many difficulties maintaining viral suppression. 
What do you think some of them are? Do you think your patients face similar challenges? If you 
could initiate a program to help patients overcome these challenges, what would you do?  
 
 
 
 
 
 
